483 results on '"G. Savarese"'
Search Results
2. Prediction of all-cause mortality using a multisensor implantable defibrillator algorithm for HF monitoring
- Author
-
A D'onofrio, M Manzo, M Bertini, L Santini, G Savarese, A Dello Russo, V E Santobuono, C Lavalle, M Viscusi, C Amellone, R Calvanese, A Santoro, M Ziacchi, S Valsecchi, and L Calo
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Funding Acknowledgements Type of funding sources: None. Background The HeartLogic algorithm combines multiple implantable defibrillator (ICD) sensor data and has proved to be a sensitive and timely predictor of impending heart failure (HF) decompensation. Purpose We determined if remotely monitored data from this algorithm can be used to identify patients at high risk of mortality. Methods The HeartLogic feature was activated in 568 ICD patients from 26 centers. Results During a median follow-up of 26 months [25th–75th percentile: 16-37], 1200 HeartLogic alerts were recorded in 370 (65%) patients. Overall, the time IN the alert state was 13% of the total observation period (151 out of 1159 years) and 20% of the follow-up period of the 370 patients with alerts. During follow-up, 55 patients died (37 in the group with alerts). Experiencing any alert episode was associated with a substantially increased risk of death [hazard ratio (HR): 2.08, 95% confidence interval (CI): 1.16–3.73, P = 0.039]. Additionally, a time IN alert ≥20% was associated with death (HR: 4.07, 95%CI: 2.19-7.54, p Conclusions The HeartLogic algorithm provides an index that can be used to identify patients at higher risk of all-cause mortality. The index status identifies periods of significantly increased risk of death.
- Published
- 2023
- Full Text
- View/download PDF
3. Combination of device-detected heart failure status and sleep-disordered breathing for the prediction of atrial fibrillation occurrence
- Author
-
F Vitali, M Bertini, A D'onofrio, G Vitulano, L Calo', G Savarese, V E Santobuono, A Dello Russo, A Mattera, A Santoro, R Calvanese, G Arena, S Valsecchi, A Mazza, and G Boriani
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Funding Acknowledgements Type of funding sources: None. Aims Patients with atrial fibrillation (AF) frequently experience sleep disorder breathing, and both conditions are highly prevalent in presence of heart failure (HF). We explored the association between sleep apnea (SA) and the HF status and the incidence of AF in patients with implantable defibrillators (ICD). Methods Data were prospectively collected from 411 consecutive HF patients with ICD. The HF status was measured by the multisensor HeartLogic Index, and the ICD-measured Respiratory Disturbance Index (RDI) was computed to identify severe SA. The endpoints were: daily AF burden of ≥5minutes, ≥6hours and ≥23hours. Results During a median follow-up of 26 months, the time IN-alert HF state was 13% of the total observation period, according to the HeartLogic algorithm (Index >16). The RDI value was ≥30 episodes/h (severe SA) during 58% of the observation period. An AF burden of ≥5 minutes/day was documented in 139 (34%) patients, ≥6 hours/day in 89 (22%) patients, and ≥23 hours/day in 68 (17%) patients. The IN-alert HF state was independently associated with AF regardless of the daily burden threshold: hazard ratios from 2.17 for ≥5 min/day to 3.43 for ≥23 h/day (p Conclusions In patients with heart failure (HF) and implantable defibrillators (ICD), the occurrence of atrial fibrillation (AF) was independently associated with the worsened HF status measured by a multisensor ICD algorithm and with ICD-diagnosed severe sleep apnea (SA). The HF status was independently associated with AF regardless of the daily burden, while severe SA was mainly associated with shorter AF episodes. The coexistence of these two conditions occurs rarely but is associated with a very high rate of AF occurrence.
- Published
- 2023
- Full Text
- View/download PDF
4. Left-bundle branch block, an alert for cardiac resynchronization therapy
- Author
-
P Gatti, I Kristjansdottir, A Azari, M Anselmino, S Lind, G Savarese, C Linde, and F Gadler
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Medtronic. Background Left bundle branch block (LBBB) might be the first finding of cardiovascular diseases but it is also the target of cardiac resynchronization therapy (CRT) in heart failure (HF) with reduced ejection fraction (HFrEF). LBBB prognosis and the implication of CRT in an unselected real-world setting are of great potential clinical impact. Methods A central ECG database together with national registries has been screened to identify LBBB patients. Cox models were fitted to assess the hazard ratio (HR) of death, cardiovascular death (CVD) and HF hospitalization (HFH) according to gender and CRT use. A subdistribution of the hazard ratio (SHR) was used to account for non-cardiovascular death as a competing risk. Logistic regression was fitted to investigate characteristics associated with CRT use. Results Of 5359 patients with LBBB and QRS duration over 150ms, 36% were female. The median age was 76 years and males had a significantly higher risk of death after 5 years from the LBBB diagnosis. CRT, when indicated, has a large benefit on all-causes of death (HR: 0.53, 95% confidence intervals (CI): 0.42-0.67), CVD (HR: 0.53 CI: 0.39-0.71) and HFH (HR: 0.71 CI: 0.60-0.82), especially in the first 5 years after the indication. These results are consistent with the competing risk analysis. Conclusion In an unselected LBBB population, CRT is underused but extremely beneficial. Therefore it’s crucial to find ways of better implementing and understanding CRT utilization, focusing on characteristics that influence recommendations.
- Published
- 2023
- Full Text
- View/download PDF
5. What determines who gets cardiac resynchronization therapy in europe?
- Author
-
P Gatti, T Thorvaldsen, L Benson, C Normand, G Savarese, U Dahlstrom, A Maggioni, L H Lund, C Linde, and K Dickstein
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Supported by Swedish Heart and Lung foundation and Stockholm County Council. Background/Introduction Cardiac resynchronization therapy (CRT) is a valuable treatment in selected patients with heart failure (HF) but is still underutilized. Aim We compared three informative data sources, which enrolled patients with HF at different organization setting and identified clinical, organizational, and level of care factors linked to CRT implantation in these cohorts. Methods Data from three large cohorts of patients with HF were compared. Patients with HF with reduced ejection fraction (HFrEF) in an ESC HF-Long Term Registry (ESC-HF-LT, n=25,621), a National HF Registry - Swede HF (n=156,621) and in the ESC-CRT Survey II (n=11088, all receiving CRT across 42 ESC countries), contributed data to the analysis. The ESC Survey II recruited patients at implanting centers, ESC-HF-LT at HF centers, whereas SwedeHF enrolled HF patients at different levels of care. Firstly, we compared patient characteristics, socio-economic and organizational factors between cohorts as well as between overlapping countries participating both in CRT Survey II and ESC HF LT. Secondly, we identified independent predictors of CRT use in the two registries using multivariable logistic regressions. Results Of the 1031 patients in ESC-HF-LT and the 5008 patients in Swede-HF, CRT was not used in 53-75 % of guideline- indicated patients. Women constituted 22% and median age ranged between 68-72 years. Guideline Directed Medical Therapy (GDMT), atrial fibrillation, previous myocardial infarction (SwedeHF) and HF hospitalization (ESC-HF-LT) was associated with more CRT use as was enrollment at university hospital and follow-up at HF center/Hospital. In Swede-HF above median income and higher education level were also independently associated with use of CRT. In the ESC-CRT Survey II (n=11.088) all patients received CRT with differences in the clinical indications between countries. Conclusion(s) CRT is an important treatment option for eligible patients with HF, which is still largely underused. The findings reported demonstrate that awareness of CRT indications as well as demographics, organizational and economic factors play an important role in CRT utilization.
- Published
- 2023
- Full Text
- View/download PDF
6. Patient acceptance of subcutaneous versus transvenous defibrillator systems: A multi‐center experience
- Author
-
Luca Santini, Alessandro Vicentini, Mariolina Lovecchio, Filippo Lamberti, Davide Giorgi, Stefano De Vivo, 'S-Icd Rhythm Detect' Investigators, Giovanni Bisignani, Giovanni Carreras, Sergio Valsecchi, Antonio Scalone, Roberto Rordorf, Eduardo Celentano, Luca Checchi, Stefano Viani, G. Savarese, Luca Ottaviano, and Pietro Francia
- Subjects
Heart Failure ,medicine.medical_specialty ,Ejection fraction ,business.industry ,Stroke Volume ,Implantable defibrillator ,Positive patient ,medicine.disease ,Patient acceptance ,Defibrillators, Implantable ,Distress ,Treatment Outcome ,Surveys and Questionnaires ,Physiology (medical) ,Heart failure ,Internal medicine ,medicine ,Humans ,Female ,In patient ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background The subcutaneous ICD (S-ICD) is an effective alternative to the transvenous ICD. No study has yet compared S-ICD and transvenous ICD by assessing patient acceptance as a patient-centered outcome. Objective To evaluate patient acceptance of the S-ICD and to investigate its association with clinical and implantation variables. In patients with symptomatic heart failure and reduced ejection fraction (HFrEF), the acceptance of the S-ICD was compared with a control group of patients who received a transvenous ICD. Methods Patient acceptance was calculated with the Florida Patient Acceptance Survey (FPAS) which measures four factors: return to function (RTF), device-related distress (DRD), positive appraisal (PA), and body image concerns (BIC). The survey was administered 12 months after implantation. Results 176 patients underwent S-ICD implantation. The total FPAS and the single factors did not differ according to gender, body habitus, or generator positioning. Patients with HFrEF had lower FPAS and RTF. Younger patients showed better RTF (75 [56-94] versus 56 [50-81], p=0.029). Patients who experienced device complications or device therapies showed higher DRD (40 [35-60] versus 25 [10-50], p=0.019). Patients with HFrEF receiving the S-ICD had comparable FPAS, RTF, DRD, and BIC to HFrEF patients implanted with the transvenous ICD while exhibited significantly better PA (88 [75-100] versus 81 [63-94], p=0.02). Conclusions Our analysis revealed positive patient acceptance of the S-ICD, even in groups at risk of more distress such as women or patients with thinner body habitus, and regardless of the generator positioning. Among patients receiving ICDs for HFrEF, S-ICD was associated with better PA versus transvenous ICD. This article is protected by copyright. All rights reserved.
- Published
- 2021
- Full Text
- View/download PDF
7. Performance of a multisensor implantable defibrillator algorithm for HF monitoring in presence of comorbidities
- Author
-
V E Santobuono, V Tavoletta, M Manzo, L Calo', M Bertini, L Santini, G Savarese, A Dello Russo, M Viscusi, C Lavalle, C Amellone, R Calvanese, S Valsecchi, and S Favale
- Subjects
General Engineering ,General Earth and Planetary Sciences ,Cardiology and Cardiovascular Medicine ,General Environmental Science - Abstract
Background Cardiovascular and non-cardiovascular comorbidities are common in heart failure (HF) patients and impact disease severity and prognosis. Select modern implantable defibrillators (ICDs) are equipped with multisensor algorithms for HF monitoring. The HeartLogic index combines multiple ICD-based sensor data (heart rate, heart sounds, thoracic impedance, respiration, activity), and the associated alert has proved to be a sensitive and timely predictor of impending HF decompensation in cardiac resynchronization therapy (CRT-D) patients The algorithm was developed using data from CRT-D patients; the performance in non-CRT ICD patients and the impact of selected comorbidities on performance requires further study. Methods The HeartLogic feature was activated in 568 ICD patients (410 with CRT) from 26 centers. The median follow-up was 25 months [25th–75th percentile: 15–35]. Results During follow-up, 97 hospitalizations were reported (53 cardiovascular) and 55 patients died. We recorded 1200 HeartLogic alerts (0.71 alerts/patient-year) in 370 patients. Overall, the time IN the alert state was 13% of the total observation period. The rate of cardiovascular hospitalizations or death was 0.48/patient-year (95% CI: 0.37–0.60) with the HeartLogic IN alert state and 0.04/patient-year (95% CI: 0.03–0.05) OUT of alert state, with an incidence rate ratio of 13.35 (95% CI: 8.83–20.51, p13% was associated with the occurrence of the combined endpoint of cardiovascular hospitalization or death (HR: 2.54, 95% CI: 1.61–4.01, p Conclusions The burden of HeartLogic alerts appears similar between CRT and non-CRT patients, while patients with AF and CKD seem more exposed to alerts. Nonetheless, the ability of the HeartLogic algorithm to identify patients during periods of significantly increased risk of clinical events is confirmed regardless of the type of device, the presence of AF, or CKD. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
- Full Text
- View/download PDF
8. Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry
- Author
-
V N Nguyen, F Lindberg, U Dahlstrom, L H Lund, and G Savarese
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Introduction The VICTORIA trial demonstrated the efficacy and safety of vericiguat in patients with worsening heart failure (HF) and an ejection fraction (EF) of Purpose We calculated the proportions of patients who would be eligible for vericiguat according to trial, guideline, and labelling scenarios in a large and unselected real-word HF population, and compared eligible to ineligible populations for patient characteristics and outcomes. Methods From the Swedish HF Registry (SwedeHF), 41,635 patients with EF Results Eligibility for vericiguat based on the trial, guideline, and labelling criteria were 21.2%, 25.7%, and 44.5%, respectively (Figure 1). The criteria with major impacts on eligibility were: 1) in the trial scenario - inclusion criteria: recent HFH (within 6 months) and elevated NT-proBNP (met by 47.5% and 74.4% of the population, respectively), exclusion criteria - nitrate use (14.0%); 2) in the guideline scenario: recent HFH and HF duration longer than 6 months (as a proxy for optimal medical therapy) (47.5% and 57.6%, respectively); 3) in the labelling scenario: recent HFH (47.5%). In patients with EF Conclusion In a large and contemporary real-world cohort of HF with EF Funding Acknowledgement Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Bayer AG
- Published
- 2022
- Full Text
- View/download PDF
9. Implantable defibrillator-detected heart failure status predicts ventricular tachyarrhythmias
- Author
-
P Compagnucci, M Casella, V Bianchi, A Giano, L Calo', M Bertini, L Santini, G Savarese, V E Santobuono, A Mattera, C Lavalle, C Amellone, C La Greca, and A Dello Russo
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background The occurrence of ventricular tachyarrhythmias is associated with increased mortality and hospitalizations for heart failure in implantable cardioverter defibrillator (ICD) patients. Nonetheless, the temporal relationship between heart failure worsening and ventricular tachyarrhythmias has been scarcely explored so far. Purpose We hypothesized that in patients with heart failure and reduced ejection fraction with ICDs, physiological sensor-based heart failure status, as reflected in the HeartLogic index, would predict appropriate device therapies for ventricular tachyarrhythmias (shocks and antitachycardia pacing). Methods and results 568 patients implanted with ICDs (n=410, 72%) or cardiac resynchronization therapy-defibrillators (CRT-D, n=158, 28%) endowed with the HeartLogic algorithm were included in this prospective observational multicenter analysis. Over a follow-up of 25 [25th-75th percentile: 15–35] months, 122 (21%) patients received an appropriate device therapy (shock, n=74, 13%), while the HeartLogic index crossed the threshold value 1200 times (0.71 alerts/patient-year) in 370 subjects (65%). The occurrence of at least one HeartLogic alert was significantly associated with both appropriate shocks (HR: 2.44, 95% CI: 1.49–3.97, p=0.003) and any ICD therapies (HR: 1.95, 95% CI: 1.37–2.85, p=0.003). Using a time-dependent Cox model, the weekly IN-alert state was the strongest predictor of ICD shocks (HR: 2.94, 95% CI: 1.73–5.01, p Conclusions The HeartLogic index is an independent predictor of appropriate defibrillator therapies. The combined index and its individual physiological components change well before the arrhythmic event, suggesting the existence of a window of opportunity to prevent shocks. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
- Full Text
- View/download PDF
10. Device-based remote monitoring strategies for guided management of patients with heart failure: a systematic review and meta-analysis
- Author
-
A Zito, G Princi, G F Romiti, S Basili, G Liuzzo, T Sanna, A Restivo, G Ciliberti, C Trani, F Burzotta, A Cesario, G Savarese, F Crea, and D D'Amario
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background Preclinical predictors of worsening heart failure can be monitored by implanted devices and may support the management of patients with heart failure. However, clinical results of such an approach are controversial. Purpose We aimed to assess if guided heart failure management according to device-based remote monitoring strategies is more effective than standard therapy. Methods A comprehensive literature research for randomized controlled trials (RCTs) comparing a strategy of guided heart failure management versus standard therapy was performed on PubMed, Embase, and CENTRAL databases. Incidence rate ratios (IRRs) and associated 95% confidence intervals (CIs) were calculated using the Poisson regression model with random study effects. The primary outcome was a composite of all-cause death and hospitalizations for heart failure. Secondary endpoints included the individual components of the primary outcome. Results A total of 9216 patients from 14 RCTs were included. The average follow-up duration was of 16 months. Compared with standard therapy, guided heart failure management reduced the risk of the composite of all-cause death and hospitalizations for heart failure (IRR 0.86, 95% CI 0.79–0.94, p Conclusion Device-based remote monitoring systems as a tool to guide the management of patients with heart failure were associated with a valuable reduction in the risks of death, hospitalizations for heart failure, and the composite of both, supporting their routine use in clinical practice. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
- Full Text
- View/download PDF
11. Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction
- Author
-
D Stolfo, F Lindberg, L Lund, G Sinagra, U Dahlstrom, G Rosano, and G Savarese
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background In heart failure with mildly reduced ejection fraction (HFmrEF) European guidelines recommend the use of antineurohormonal therapies with a low level of evidence (IIb C) based on data from subgroup and post-hoc analyses of randomized clinical trials (RCTs). Data from large and unselected real-world HFmrEF populations are lacking. Purpose To assess the association between renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) and beta-blockers and outcomes in HFmrEF. Methods Data from patients with HFmrEF (EF: 40–49%) from the Swedish HF Registry during 2000–2018 were considered. The association between each of RASI/ARNI and beta-blockers treatment and cardiovascular (CV)mortality/heart failure hospitalization (HFH) and all-cause mortality was assessed by Cox proportional hazard models in a 1:1 propensity score-matched cohort. Since propensity score (PS) matching might lead to a selection of the study population and reduction of the sample size, as consistency analysis Cox proportional hazard models were also fitted in the overall cohort adjusting rather than matching for PS. Results Of 12421 patients with HFmrEF (mean age 74±12 years, 64% males), 10419 (84%) received RASI/ARNI, 10941 (88%) received beta-blockers. Patients treated with both RASI/ARNI and beta-blockers were 9332 (75%), 2696 (22%) patients received one drug (9% RASI/ARNI, 13% beta-blockers) and 393 (3%) none. Main predictors of treatments use were younger age, female sex (only for beta-blockers), outpatient setting, referral to specialty care and nurse-led HF clinic. Lower NT-proBNP levels were associated with more use of RASI/ARNI but less use of beta-blockers. Better renal function was predictive of RASI/ARNI use. Comorbidities were associated with less use of treatments, in particular atrial fibrillation for RASI/ARNI, and COPD for RASI/ARNI and beta-blockers. In the matched cohorts including 3854 for RASI/ARNI analyses and 2940 patients for beta-blockers, RASI/ARNI (HR=0.90, 95% CI: 0.83–0.97) and beta-blocker (HR=0.82, 95% CI: 0.75–0.91) use were associated with a statistically significant lower risk of CV mortality/HF hospitalization (Figure 1) and of all-cause mortality (HR=0.72, 95% CI: 0.67–0.78 and HR=0.77, 95% CI: 0.70–0.85, respectively). Consistency analysis confirmed results. Conclusions RASI/ARNI and beta-blockers were largely used in this large real-world cohort of patients with HFmrEF to treat comorbidities. Their use was associated with lower risk of mortality/morbidity and the magnitude of the associations was somehow similar to what observed in subgroup/post-hoc analyses of RCTs. Our findings call for a fast implementation of guidelines recommendations on HFmrEF treatment. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
- Full Text
- View/download PDF
12. Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study
- Author
-
G Savarese, B Bozkurt, S Adamsson Eryd, J Bodegard, L H Lund, M Thuresson, O Vardeny, and T Kishi
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background Use of guideline-directed medical therapies (GDMTs) in patients with heart failure (HF) with reduced ejection fraction (HFrEF) – such as renin–angiotensin–aldosterone system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and angiotensin receptor neprilysin inhibitors – is suboptimal, especially after hospitalization for HF (hHF). Dapagliflozin was the first sodium–glucose co-transporter-2 inhibitor approved in patients with HFrEF. In the DAPA-HF study, dapagliflozin decreased the risk of hHF and mortality in patients with HFrEF (with or without type 2 diabetes) compared with placebo. Little is known about the real-world characteristics and treatment profiles of patients initiating dapagliflozin after hHF in clinical practice. Purpose EVOLUTION HF aims to describe characteristics and real-world treatment patterns in patients who initiated GDMTs following hHF. Using data available to date, we focused on dapagliflozin use in two countries (Japan and Sweden). Methods EVOLUTION HF is a multinational observational, longitudinal cohort study using claims and electronic health record databases, which included 514,869 patients with hHF during the study period. Adult patients who initiated dapagliflozin between December 2020 and September 2021 (Japan) or December 2021 (Sweden) were identified and included if they initiated dapagliflozin 10 mg once daily during hHF or within 12 months after a hHF discharge. Patient characteristics and treatment profile at index (initiation of dapagliflozin) are reported overall and by country. Results Overall, 7023 patients were included (3515 from Japan, 3508 from Sweden; Table 1); the mean age was 73±13 years and 70% were male. The median lengths of the hHF leading to dapagliflozin initiation were 16 (interquartile range [IQR] 9–26) days in Japan and 4 (IQR 2–7) days in Sweden. Overall prevalences of atrial fibrillation, chronic kidney disease, diabetes and established cardiovascular disease were 50%, 23%, 34% and 57%, respectively. Of the 7023 patients who initiated dapagliflozin during hHF or within 12 months of hHF discharge, 45%, 62%, 75% and 87% of patients initiated dapagliflozin in hospital/within 7 days of discharge or within 1, 3 or 6 months of discharge, respectively. Japan had a higher proportion of patients who initiated dapagliflozin in hospital/within 7 days of hHF discharge compared with Sweden (64% vs 27%; Figure 1). At dapagliflozin initiation, 37% and 74% of patients in Japan and Sweden, respectively, had three or four other GDMTs. Conclusions Patients who initiated dapagliflozin following hHF often had comorbidities associated with increased risk of adverse cardiorenal outcomes. Timing of dapagliflozin initiation and use of other GDMTs at index varied between countries. A large proportion of patients initiated dapagliflozin more than 1 month after a hHF or in addition to three or four other GDMTs, indicating an opportunity for earlier dapagliflozin use in patients with HF. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): AstraZeneca
- Published
- 2022
- Full Text
- View/download PDF
13. Association between atrial fibrillation and cardiac implantable defibrillator detected heart failure status
- Author
-
F Vitali, V Tavoletta, A Giano, L Calo, L Santini, G Savarese, A Dello Russo, VE Santobuono, A Mattera, C Lavalle, C Amellone, D Pecora, and M Bertini
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Funding Acknowledgements Type of funding sources: None. Background In heart failure (HF) patients, atrial fibrillation (AF) is a common comorbidity and is associated with a worse prognosis. Implantable defibrillator (ICD) diagnostics allow continuous monitoring of atrial high-rate events (AHRE), as a surrogate of AF, and are equipped with algorithms for HF monitoring. We evaluated the association between the values of the multisensor HF HeartLogic Index and the incidence of AF, and assessed the performance of the Index in detecting follow-up periods of significantly increased AF risk. Methods The HeartLogic feature was activated in 568 ICD patients. The median follow-up was 25 months [25th–75th percentile: 15-35]. The HeartLogic algorithm calculates a daily HF index and identifies periods IN the alert state on the basis of a configurable threshold. The endpoints were: daily AF burden of ≥5 minutes, ≥6 hours and ≥23 hours. Results The HeartLogic index crossed the threshold value 1200 times (0.71 alerts/patient-year). The time IN the alert state was 13% of the total observation period. During the observation period, an AF burden of ≥5 minutes/day was documented in 183 (32%) patients, ≥6 hours/day in 118 (21%) patients, and ≥23 hours/day in 89 (16%). On using a time-dependent Cox model, the weekly time IN the alert state was independently associated with an AF burden of ≥5 minutes/day (HR:1.95, 95%CI:1.22-3.13, p=0.005), ≥6 hours/day (HR:2.66, 95%CI:1.60-4.44, p Conclusions The HeartLogic alert state was independently associated with AF occurrence. The intervals of time defined by the algorithm as periods of increased risk of HF allow risk stratification of AF according to various thresholds of daily burden.
- Published
- 2022
- Full Text
- View/download PDF
14. Predictors of heart failure events detected by a multisensor implantable defibrillator algorithm
- Author
-
V Santobuono, V Tavoletta, M Manzo, L Calo’, M Bertini, L Santini, G Savarese, A Dello Russo, M Viscusi, C Lavalle, C Amellone, C La Greca, S Valsecchi, and S Favale
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Funding Acknowledgements Type of funding sources: None. Background Cardiovascular and non-cardiovascular comorbidities are common in heart failure (HF) patients and determine disease severity and prognosis. Select modern implantable defibrillators (ICDs) are equipped with multisensor algorithms for HF monitoring. The HeartLogic index combines multiple ICD-based sensor data (heart rate, heart sounds, thoracic impedance, respiration, activity), and the associated alert has proved to be a sensitive and timely predictor of impending HF decompensation in cardiac resynchronization therapy (CRT) patients. Purpose This analysis aims to investigate the performance of the algorithm in non-CRT patients, as well as in relation to the presence of comorbidities. Methods The HeartLogic feature was activated in 568 ICD patients (410 with CRT) from 26 centers. The median follow-up was 25 months [25th–75th percentile: 15-35]. Results We recorded 1200 HeartLogic alerts (0.71 alerts per patient-year) in 370 patients. Among patient characteristics, atrial fibrillation (AF) at implantation (HR: 1.62, 95%CI: 1.27-2.07, p Conclusions The burden of HeartLogic alerts appears similar between CRT and non-CRT patients, while patients with AF and CKD seem more exposed to alerts. ICD-measured thoracic impedance is sensitive to the fluid overload that characterizes kidney disease, as well as the first and third heart sound amplitudes seem sensitive to the reduced ventricular efficiency during AF. Nonetheless, ICD sensors seem to equally contribute to the HeartLogic alerts in all patient subgroups.
- Published
- 2022
- Full Text
- View/download PDF
15. P51 HYBRYD TREATMENT FOR CORONARY ARTERY DISEASE CONCOMITANT WITH MINIMALLY INVASIVE CARDIAC VALVE SURGERY
- Author
-
E Ramoni, M Del Giglio, R Ceresa, G Savarese, M Lamarra, E Di Chicco, and C Grattoni
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Cardiac valvular surgery concomitant with coronary artery bypass grafting has a higher mortality than isolated valve surgery. Therefore, a hybrid approach that combines the benefits of the low risk of percutaneous coronary angioplasty (PCI) with those of minimally invasive valve surgery, should be considered. At present, data on hybrid valve/PCI procedures are limited to clinical cases and small cases, in which the PCI procedure is usually followed by surgery after about 3 weeks. We report our experience in which valve surgery was first performed with a minimally invasive approach (minithoracotomy or ministernotomy), then followed by coronary revascularization with PCI, to reduce the risks of post–surgical bleeding due to anti–aggregating therapy, in a non–randomized but consecutive case. Between July 2019 and June 2021, 22 patients were treated. Median of the days between surgery and PCI was 8, median of total hospitalization was 13 days. In 6 patients the surgical approach was a ministernotomy, in 16 was performed a right minithoracotomy. In 14 (64%) patients PCI was performed on single coronary vessel, in 5 (22.5%) on 2 coronary vessels and in 3 (13.5%) on 3 coronary vessels. There were no reinterventions for postoperative bleeding. One patient presented gastro–intestinal bleeding from a colon polyp. No patients died during hospitalization, nor at the follow–up performed by telephone every 6 months. No patients required valve reintervention or coronary artery bypass during hospitalization or follow–up. One patient underwent a new PCI procedure at 7 months. In conclusion, the hybrid approach consisting of minimally invasive valve surgery followed by PCI may offer an alternative to the standard but more complex operation of coronary artery bypass grafting plus valve surgery through complete sternotomy.
- Published
- 2022
- Full Text
- View/download PDF
16. Single- and multi-site pacing strategies for optimal cardiac resynchronization therapy: impact on device longevity and therapy cost
- Author
-
Sergio Valsecchi, T Infusino, Giovanni B. Forleo, Danilo Ricciardi, G. Savarese, Laura Cipolletta, Matteo Bertini, Michele Manzo, Luca Santini, Giovanni Licciardello, Valter Bianchi, Girolamo D’Arienzo, Antonio D'Onofrio, Francesca Fabbri, Pasquale Notarstefano, Giovanni Russo, and Monica Campari
- Subjects
Battery (electricity) ,medicine.medical_specialty ,Time Factors ,Cost ,Apex ,CRT ,Longevity ,Quadripolar ,Cardiac Resynchronization Therapy Devices ,Humans ,Treatment Outcome ,Cardiac Resynchronization Therapy ,Heart Failure ,medicine.medical_treatment ,media_common.quotation_subject ,Cardiac resynchronization therapy ,Socio-culturale ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,medicine ,030212 general & internal medicine ,media_common ,business.industry ,Multi site ,Ventricular pacing ,Cost analysis ,Cardiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
Multiple left ventricular pacing strategies have been suggested for improving response to cardiac resynchronization therapy (CRT). However, these programming strategies may sometimes entail accepting configurations with high pacing threshold and accelerated battery drain. We assessed the feasibility of predefined pacing programming protocols, and we evaluated their impact on device longevity and their cost-impact. We estimated battery longevity in 167 CRT-D patients based on measured pacing parameters according to multiple alternative programming strategies: single-site pacing associated with lowest threshold, non-apical location, longest interventricular delay, and pacing from two electrodes. To determine the economic impact of each programming strategy, we applied the results of a model-based cost analysis using a 15-year time horizon. Selecting the electrode with the lowest threshold resulted in a median device longevity of 11.5 years. Non-apical pacing and interventricular delay maximization were feasible in most patients and were obtained at the price of a few months of battery life. Device longevity of > 10 years was preserved in 87% of cases of non-apical pacing and in 77% on pacing at the longest interventricular delay. The mean reduction in battery life when the second electrode was activated was 1.5 years. Single-site pacing strategies increased the therapy cost by 4–6%, and multi-site pacing by 12–13%, in comparison with the lowest-cost scenario. Modern CRT-D systems ensure effective pacing and allow multiple optimization strategies for maximizing service life or for enhancing effectiveness. Single- or multi-site pacing strategies can be implemented without compromising device service life and at an acceptable increase in therapy cost.
- Published
- 2020
- Full Text
- View/download PDF
17. Implantable cardioverter defibrillator multisensor monitoring during home confinement caused by the covid-19 pandemic
- Author
-
Sergio Valsecchi, A Talarico, G. Giubilato, C La Greca, Luca Santini, Vincenzo Ezio Santobuono, Giuseppe Arena, Matteo Ziacchi, Antonio D'Onofrio, G. Savarese, Michele Manzo, C. Carriere, Federico Guerra, Igor Diemberger, and L Calo
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Early signs ,medicine.medical_treatment ,Cardiac resynchronization therapy ,Implantable cardioverter-defibrillator ,medicine.disease ,Physiology (medical) ,Heart failure ,Emergency medicine ,Pandemic ,Heart rate ,medicine ,Device Therapy - Home and Remote Patient Monitoring ,Decompensation ,AcademicSubjects/MED00200 ,Cardiology and Cardiovascular Medicine ,business - Abstract
Funding Acknowledgements Type of funding sources: None. Background Utilization of remote monitoring platforms was recommended amidst the COVID-19 pandemic. The HeartLogic algorithm combines data from multiple implantable cardioverter defibrillator (ICD) sensors (first and third heart sounds, intrathoracic impedance, respirations, night heart rate, and patient activity) to provide integrated data that may allow for detection of early signs of worsening HF. Purpose We examined whether the HeartLogic platform may elucidate behavioral changes that impact HF decompensation, and the possible consequences of home confinement caused by the COVID-19 pandemic. Methods The Italian lockdown was imposed from March 8th to May 18th. On March 8th 2020, the HeartLogic feature was active in 349 ICD and cardiac resynchronization therapy ICD patients at 20 Italian centers. The period from January 1st to July 19th was divided in 3 phases: Pre-Lockdown (weeks 1-11), Lockdown (weeks 12-20), Post-Lockdown (weeks 21-29). Results Immediately after the implementation of stay at home orders (week 12) we observed a significant drop in median activity level (65min [36-103] in week 12 vs. 101min [61-140] in Pre-Lockdown; p Conclusions The system was sensitive to the behavioral changes occurred during the lockdown, i.e. decrease in activity. However, the home confinement had no impact on the other sensors. The higher rate of HeartLogic alerts during lockdown and the increase in the median index after 8 weeks of home confinement suggest the worsening of the HF status, possibly explained by the behavioral changes. Nonetheless, the management of the HF detected events (actions performed and management strategy) was not impacted by the restrictions.
- Published
- 2021
18. Effective nonapical left ventricular pacing with quadripolar leads for cardiac resynchronization therapy
- Author
-
Giovanni B. Forleo, Carmelo Gerosa, Sergio Valsecchi, Stefano Donzelli, G. Savarese, Luca Santini, S. Badolati, Vincenzo Schillaci, Gianfranco Mitacchione, Alessio Gasperetti, Gregorio Covino, Mariolina Lovecchio, Carlo Lavalle, Massimo Sassara, Francesco Solimene, Marco Schiavone, and Domenico G. Della Rocca
- Subjects
Heart Failure ,medicine.medical_specialty ,Phrenic nerve stimulation ,business.industry ,medicine.medical_treatment ,Heart Ventricles ,Cardiac Resynchronization Therapy Devices ,Treatment outcome ,Cardiac resynchronization therapy ,Safety margin ,Ventricular pacing ,Electrodes, Implanted ,Cardiac Resynchronization Therapy ,Treatment Outcome ,Interquartile range ,Internal medicine ,medicine ,Cardiology ,Humans ,Cardiology and Cardiovascular Medicine ,Lead (electronics) ,business - Abstract
Background: Current guidelines recommend avoiding apical left ventricular (LV) pacing for cardiac resynchronization therapy (CRT). Aims: We investigated the feasibility of nonapical pacing with the current quadripolar LV lead technology. Methods: We analyzed consecutive patients who received CRT with an LV quadripolar lead. The postimplantation position of each electrode of the LV lead was designated as basal, mid, or apical. The pacing capture threshold (PCT) and phrenic nerve stimulation (PNS) threshold were assessed for each electrode. Results: We enrolled 168 patients. A total of 8 CRT defibrillators were from Biotronik (with Sentus OTW QP leads), 98 were from Boston Scientific (with 21 Acuity X4 Spiral and 77 Acuity X4 Straight leads), and 62 from St. Jude Medical (with Quartet leads). The median (interquartile range) number of electrodes at nonapical segments per patient was 3 (1–4) with Biotronik Sentus leads, 4 (3–4) with spiral design Boston Scientific leads, 4 (3–4) with straight Boston Scientific leads, and 3 (3–4) with St. Jude Medical Quartet leads (P = 0.045). Three patients (38%) with Biotronik Sentus leads, 21 (100%) with spiral design Boston Scientific leads, 69 (90%) with straight design Boston Scientific leads, and 49 (79%) with St. Jude Medical Quartet leads (P < 0.001) had at least 1 electrode located at nonapical segments linked with a PNS PCT safety margin of more than 2 V. During the 6month follow up, PNS was detected in 4 patients and was eliminated with reprogramming. No significant changes in PCT were detected during follow up. Conclusions: Quadripolar leads allowed nonapical pacing with acceptable electrical parameters in the majority of CRT recipients, although differences were found among the currently available devices.
- Published
- 2021
19. Safety of Omitting Defibrillation Efficacy Testing With Subcutaneous Defibrillators: A Propensity-Matched Case-Control Study
- Author
-
Valter Bianchi, Giovanni Bisignani, Federico Migliore, Mauro Biffi, Gerardo Nigro, Stefano Viani, Fabrizio Caravati, Luca Checchi, Pietro Francia, Paolo De Filippo, Domenico Pecora, Carlo Lavalle, Antonio Scalone, Pietro Rossi, Pietro Palmisano, Giovanni Licciardello, Roberto Ospizio, Mariolina Lovecchio, Sergio Valsecchi, Antonio D’Onofrio, A. D’Onofrio, V. Tavoletta, S. De Vivo, P. Pieragnoli, G. Ricciardi, L. Perrotta, L. Ottaviano, I. Diemberger, M. Ziacchi, C. Martignani, V. Russo, A. Rago, E. Ammendola, M.G. Bongiorni, R. De Lucia, A. Di Cori, L. Paperini, L. Segreti, E. Soldati, G. Zucchelli, F. Palano, C. Adduci, P. Ferrari, C. Leidi, A. Dello Russo, M. Casella, F. Guerra, L. Cipolletta, S. Molini, S. Pedretti, M. Giammaria, M.T. Lucciola, C. Amellone, M. Accogli, B. Schintu, G. Tola, A. Setzu, E. Pisanò, G. Milanese, S. De Bonis, C. La Greca, B. Sarubbi, D. Colonna, E. Romeo, S. Sala, P. Mazzone, P. Della Bella, M. Viscusi, D. Di Maggio, M. Brignoli, F. Drago, M.S. Silvetti, R. Brambilla, A. Pani, A Lupi, G. Carreras, S. Donzelli, C. Marini, A. Tordini, E. Racca, A. Gonella, G. Musumeci, G. Rossetti, E Menardi, G. P. Ballari, F. Ammirati, L. Santini, K. Mahfouz, C. Colaiaco, GB. Perego, V. Rella, G. Bertero, P. Sartori, A. Rapacciuolo, V. Liguori, A. Viggiano, G. Busacca, G. Savarese, C. Andreoli, L. Pimpinicchio, D. Pellegrini, G. Stifano, F. Romeo, D. Sergi, S. Badolati, P. Pepi, D. Nicolis, R. Rordorf, A. Vicentini, S. Savastano, B. Petracci, A. Sanzo, E. Baldi, M. Casula, F. Solimene, G. Shopova, V. Schillaci, A. Arestia, A. Agresta, A. Piro, GB. Forleo, A. Pangallo, M. Manzo, C. Esposito, F. Esposito, A. Curcio, D. Ricciardi, V. Calabrese, D. Giorgi, null Bovenzi, F. Busoni, A. Torriglia, M. Laffi, G. Gaggioli, G. Arena, V. Molendi, V. Borrello, M. Ratti, C. Bartoli, P. Capogrosso, M. Volpicelli, G. Covino, M. Mariani, M. Pagani, P. Notarstefano, M. Nesti, E. Dovellini, L. Giurlani, M. Landolina, E. Tavarelli, S. Bianchi, C. Uran, Massimo Vincenzo Bonfantino, E. Daleffe, D. Facchin, L Rebellato, V. Caccavo, M. Grimaldi, G. Katsouras, A. Coppolino, F. Lamberti, G. Lumia, C. Bellini, C. Bianchi, A Santoro, C Baiocchi, R Gentilini, S Lunghetti, and V Zacà
- Subjects
medicine.medical_specialty ,implantable ,Defibrillation ,business.industry ,cardiac ,medicine.medical_treatment ,Case-control study ,ventricular fibrillation ,cause of death ,defibrillator ,Informed consent ,Physiology (medical) ,Emergency medicine ,Propensity score matching ,medicine ,arrhythmias, cardiac ,defibrillator, implantable ,propensity score ,Cardiology and Cardiovascular Medicine ,business ,Body mass index ,arrhythmias ,Cause of death - Published
- 2021
20. First beams from the 1+ source of the ADIGE injector for the SPES Project
- Author
-
A Galatà, P Francescon, C Roncolato, G Bisoffi, M Ballan, L Bellan, J Bermudez, D Bortolato, M Comunian, A Conte, M De Lazzari, E Fagotti, F Gelain, M Manzolaro, D Marcato, V Martinelli, M Miglioranza, M F Moisio, A Monetti, E Munaron, A Pisent, M Rossignoli, M Roetta, G Savarese, and D Scarpa
- Subjects
History ,Computer Science Applications ,Education - Abstract
The ADIGE (Acceleratore Di Ioni a Grande carica Esotici) injector consists of an electrostatic 1+ beam line, equipped with ion sources able to produce a wide variety of beams, coupled to a magnetic beam line, where charge multiplication is accomplished by implementing an Electron Cyclotron Resonance (ECR) based charge breeder. The injector is totally integrated in the SPES (Selective Production of Exotic Species) beam line, to allow the post-acceleration of radioactive ions and is now in an advanced phase of installation. The electrostatic 1+beam line has been put into operation and is now producing beams from alkali metals. This contribution concerns the first results of the beam commissioning of this part of the injector, with the description of the initial debug phase and the solutions adopted to ensure a reliable and continuous operation. Preliminary results of the 1+ beam line characterization will be shown, with a comparison between simulated and measured emittances.
- Published
- 2022
- Full Text
- View/download PDF
21. P538Single- and Multi-Site Pacing Strategies for Optimal Cardiac Resynchronization Therapy: Impact on Device Longevity and Therapy Cost
- Author
-
A D\\'onofrio, Giovanni Russo, Valter Bianchi, Giovanni B. Forleo, T Infusino, Danilo Ricciardi, G. Savarese, Luca Santini, R Ospizio, G D Arienzo, Michele Manzo, Giovanni Licciardello, Matteo Bertini, A Misiani, and Sergio Valsecchi
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,media_common.quotation_subject ,Cardiac resynchronization therapy ,Multi site ,Longevity ,Physiology (medical) ,Internal medicine ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,media_common - Abstract
Funding Acknowledgements No funding Introduction Multiple left ventricular pacing strategies have been suggested for improving response to cardiac resynchronization therapy (CRT). However, these programming strategies can be obtained by accepting configurations with high pacing threshold and accelerated battery drain. We assessed the feasibility of predefined pacing programming protocols and we evaluated their impact on device longevity and their cost-impact. Methods We estimated battery longevity in 167 CRT-D (RESONATE, Boston Scientific) patients based on measured pacing parameters and according to multiple programming strategies: single-site pacing associated with lowest threshold, non-apical location, longest interventricular delay, pacing from two electrodes. To determine the economic impact of each programming strategy, we applied the results of a published model-based cost analysis to a 15-year time-horizon. Results Selecting the electrode with the lowest threshold resulted in a median device longevity of 11.5 years. Non-apical pacing and interventricular delay maximization were feasible in most patients (99% non-apical pacing, 65% RV-to-LV interval >80ms), and were obtained at the price of a few months of battery life. Device longevity of >10 years was preserved in 87% of cases of non-apical pacing and in 77% on pacing at the longest interventricular delay. The mean reduction in battery life when the second electrode was activated was 1.5 years. Single-site pacing strategies increased the therapy cost by 4-6%, and multi-site pacing by 12-13%, in comparison with the best-case scenario. Conclusions Modern CRT-D systems ensure effective pacing and allow multiple optimization strategies for maximizing service life or for enhancing effectiveness. Single- or multi-site pacing strategies can be implemented without compromising device service life and at an acceptable increase in therapy cost. Abstract Figure. Image1
- Published
- 2020
- Full Text
- View/download PDF
22. Adherence to 2016 European Society of Cardiology guidelines predicts outcome in a large real-world population of heart failure patients requiring cardiac resynchronization therapy
- Author
-
Antonio Rapacciuolo, Massimiliano Marini, Giuseppe Stabile, Pietro Palmisano, Paolo Pieragnoli, Patrizia Pepi, Assunta Iuliano, Domenico Pecora, S. Badolati, Giovanni Luca Botto, Salvatore Ivan Caico, G. Savarese, Antonio De Simone, Emanuele Bertaglia, Maurizio Malacrida, Antonio D'Onofrio, Giuseppe Arena, Giampiero Maglia, Stabile, Giuseppe, Pepi, Patrizia, Palmisano, Pietro, D'Onofrio, Antonio, De Simone, Antonio, Caico, Salvatore Ivan, Pecora, Domenico, Rapacciuolo, Antonio, Arena, Giuseppe, Marini, Massimiliano, Pieragnoli, Paolo, Badolati, Sandra, Savarese, Gianluca, Maglia, Giampiero, Iuliano, Assunta, Botto, Giovanni Luca, Malacrida, Maurizio, and Bertaglia, Emanuele
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,Cardiology ,Cardiac resynchronization therapy ,Heart failure ,Guideline ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,Humans ,Medicine ,Single-Blind Method ,Prospective Studies ,Registries ,030212 general & internal medicine ,education ,Prospective cohort study ,Survival rate ,Societies, Medical ,Aged ,Outcome ,education.field_of_study ,Ejection fraction ,business.industry ,Hazard ratio ,Stroke Volume ,Stroke volume ,Middle Aged ,medicine.disease ,Remodeling ,Europe ,Survival Rate ,Treatment Outcome ,Female ,Guideline Adherence ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Background Professional guidelines are based on the best available evidence. However, patients treated in clinical practice may differ from those included in reference trials. Objective The aim of this study was to evaluate the effects of cardiac resynchronization therapy (CRT) in a large population of patients implanted with a CRT device stratified in accordance with the 2016 European heart failure (HF) guidelines. Methods We collected data on 930 consecutive patients from the Cardiac Resynchronization Therapy MOdular REgistry. The primary end point was a composite of death and HF hospitalization. Results Five hundred sixty-three (60.5%) patients met class I indications, 145 (15.6%) class IIa, 108 (11.6%) class IIb, and 114 (12.3%) class III. After a median follow-up of 1001 days, 120 (14.7%) patients who had an indication to CRT had died and 71 (8.7%) had been hospitalized for HF. The time to the end point was longer in patients with a class I indication (hazard ratio 0.55; 95% confidence interval 0.39–0.76; P = .0001). After 12 months, left ventricular (LV) end-systolic volume had decreased by ≥15% in 61.5% (320/520) of patients whereas in 57.5% (389/676) of patients the absolute LV ejection fraction improvement was ≥5%. Adherence to class I was also associated with an absolute LV ejection fraction increase of >5% (P = .0142) and an LV end-systolic volume decrease of ≥15% (P = .0055). Conclusion In our population, ∼60% of patients underwent implantation according to the 2016 European HF guidelines class I indication. Adherence to class I was associated with a lower death and HF hospitalization rates and better LV reverse remodeling.
- Published
- 2018
- Full Text
- View/download PDF
23. Role of inflammatory markers as predictors of adverse pathological outcomes in patients with testicular cancer: a multicenter analysis
- Author
-
V. Baldassarri, C. De Nunzio, O.A. Voglino, R. Lombardo, A. Nacchia, A.F.M. Cicione, G. Savarese, L.C. Licari, C. Leonardo, Y. Al Sahli, A. Fuschi, A. Carbone, A. Pastore, A. Bove, U. Anceschi, G. Tuderti, G. Simone, A. Brassetti, A. Simonato, and R. Giaimo
- Subjects
Urology - Published
- 2021
- Full Text
- View/download PDF
24. B-PO04-060 DEVICE-RELATED DISTRESS, BODY IMAGE CONCERNS, RETURN TO FUNCTION AND POSITIVE APPRAISAL IN PATIENTS WITH SUBCUTANEOUS VERSUS TRANSVENOUS DEFIBRILLATOR
- Author
-
Antonio Scalone, Stefano Viani, Pietro Francia, Giovanni Carreras, Luca Ottaviano, Antonio D'Onofrio, G. Savarese, Silvana De Bonis, Roberto Rordorf, Eduardo Celentano, Mariolina Lovecchio, Luca Santini, Giuseppe Ricciardi, Alessandro Vicentini, and Filippo Lamberti
- Subjects
Distress ,medicine.medical_specialty ,business.industry ,Physiology (medical) ,Internal medicine ,medicine ,Cardiology ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Image (mathematics) - Published
- 2021
- Full Text
- View/download PDF
25. Towards the First Beams from the ADIGE Injector for the SPES Project
- Author
-
F. Gelain, M. Rossignoli, Marco Bellato, Michele Comunian, S. Pavinato, Thomas Thuillier, G. Bisoffi, Damiano Bortolato, L. Bellan, E. Munaron, D. Pedretti, M.F. Moisio, M. Roetta, A. Conte, D. Bondoux, P. Francescon, A. Pisent, J. Angot, D. Marcato, G. Savarese, M. O. Miglioranza, C. Roncolato, J. Bermudez, M. De Lazzari, V. Andreev, Alessio Galatà, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), and Université Grenoble Alpes (UGA)
- Subjects
History ,Instrumentation ,Nuclear engineering ,[PHYS.PHYS.PHYS-ACC-PH]Physics [physics]/Physics [physics]/Accelerator Physics [physics.acc-ph] ,7. Clean energy ,01 natural sciences ,Electron cyclotron resonance ,010305 fluids & plasmas ,Education ,law.invention ,law ,0103 physical sciences ,ion-source ,plasma ,010302 applied physics ,Physics ,instrumentation ,Plasma ,Injector ,Ion source ,Computer Science Applications ,ECR ,Medium resolution ,Beamline ,injection ,Voltage - Abstract
The ADIGE (Acceleratore Di Ioni a Grande carica Esotici) injector of the SPES (Selective Production of Exotic Species) project is now in an advanced phase of installation. Its main components have been designed following particular needs of the project: first, an Electron Cyclotron Resonance (ECR)-based Charge Breeder (SPES-CB), to boost the charge states of the radioactive ions produced at SPES and allow their post-acceleration. Then, a stable 1+ source and a complete electrostatic beam line to characterize the SPES-CB. Finally, a unique Medium Resolution Mass Spectrometer (MRMS, R=1/1000), mounted on a high voltage platform downstream the SPES-CB, to clean the radioactive beam from the contaminants induced by the breeding stage. This contribution describes the status of the injector, in particular the installation of the platform housing the MRMS, the access and safety system adopted and the first beams to be extracted from the stable 1+ source.
- Published
- 2019
- Full Text
- View/download PDF
26. Progresses in the Installation of the SPES-Charge Breeder Beam Line
- Author
-
Michele Comunian, E. Munaron, G. Bisoffi, A. Conte, M. Roetta, S. Pavinato, G. Savarese, Damiano Bortolato, F. Gelain, L. Bellan, M. Rossignoli, D. Marcato, A. Pisent, P. Francescon, M. O. Miglioranza, Marco Bellato, C. Roncolato, J. Bermudez, M. De Lazzari, V. Andreev, M.F. Moisio, Alessio Galatà, and D. Pedretti
- Subjects
010302 applied physics ,Spectrometer ,Nuclear engineering ,Charge breeding ,High voltage ,Charge (physics) ,Injector ,01 natural sciences ,Electron cyclotron resonance ,010305 fluids & plasmas ,law.invention ,Accelerator Physics ,Breeder (animal) ,Beamline ,law ,0103 physical sciences ,Measuring instrument ,Environmental science ,Instrumentation ,Mathematical Physics - Abstract
Since fall 2017, the ADIGE (Acceleratore Di Ioni a Grande carica Esotici) injector of the SPES (Selective Production of Exotic Species) project entered the installation phase. The injector includes an ECR-based charge breeder (SPES-CB) and its complete beam line, as well as a newly designed RFQ, to allow the post-acceleration of the radioactive ions produced in the so-called Target-Ion-Source system. The injector has different peculiarities, deriving from particular needs of SPES: a complete electrostatic beam line equipped with a 1+ source for test purposes, and a unique Medium Resolution Mass Spectrometer (MRMS, R~1/1000), mounted downstream the SPES-CB, to clean the radioactive beam from the contaminants induced by the breeding stage. This contribution reports about the status of the installation of the injector, describing the various technical solution adopted, and giving a realistic planning for the commission and following operation of its main parts., Proceedings of the 23th Int. Workshop on ECR Ion Sources, ECRIS2018, Catania, Italy
- Published
- 2019
- Full Text
- View/download PDF
27. Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management
- Author
-
Leonardo Calò, Valter Bianchi, Donatella Ferraioli, Luca Santini, Antonio Dello Russo, Cosimo Carriere, Vincenzo Ezio Santobuono, Chiara Andreoli, Carmelo La Greca, Giuseppe Arena, Antonello Talarico, Ennio Pisanò, Amato Santoro, Massimo Giammaria, Matteo Ziacchi, Miguel Viscusi, Ermenegildo De Ruvo, Monica Campari, Sergio Valsecchi, Antonio D’Onofrio, M Minati, C Tota, A Martino, V Tavoletta, M Manzo, F Ammirati, K Mahfouz, C Colaiaco, F Guerra, A Zorzin Fantasia, V Amato, G Savarese, D Pellegrini, L Pimpinicchio, D Pecora, C Bartoli, V.M Borrello, M Ratti, F De Rosa, F Quirino, C Tomaselli, E Marino, C Baiocchi, O De Vivo, B Baccani, C Amellone, M.T Lucciola, A Angeletti, J Frisoni, M Brignoli, A Costa, A Pangallo, F Benedetto, P Pepi, D Nicolis, B Petracci, G Giubilato, L Carbonardi, D Porcelli, B Romani, and L.M. Zuccaro
- Subjects
Male ,Logic ,medicine.medical_treatment ,defibrillator, implantable ,Cardiac Resynchronization Therapy ,Heart Rate ,Risk Factors ,Medicine ,Humans ,Cardiac Resynchronization Therapy Devices ,Aged ,risk ,Aged, 80 and over ,Heart Failure ,algorithm ,business.industry ,Original Articles ,medicine.disease ,Implantable cardioverter-defibrillator ,Defibrillators, Implantable ,Clinical Practice ,Heart failure ,Risk stratification ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Female ,Cardiology and Cardiovascular Medicine ,business ,Algorithm ,Algorithms ,hospitalization - Abstract
Supplemental Digital Content is available in the text., Background: The HeartLogic algorithm combines multiple implantable cardioverter-defibrillator sensors to identify patients at risk of heart failure (HF) events. We sought to evaluate the risk stratification ability of this algorithm in clinical practice. We also analyzed the alert management strategies adopted in the study group and their association with the occurrence of HF events. Methods: The HeartLogic feature was activated in 366 implantable cardioverter-defibrillator and cardiac resynchronization therapy implantable cardioverter-defibrillator patients at 22 centers. The median follow-up was 11 months [25th–75th percentile: 6–16]. The HeartLogic algorithm calculates a daily HF index and identifies periods IN alert state on the basis of a configurable threshold. Results: The HeartLogic index crossed the threshold value 273 times (0.76 alerts/patient-year) in 150 patients. The time IN alert state was 11% of the total observation period. Patients experienced 36 HF hospitalizations, and 8 patients died of HF during the observation period. Thirty-five events were associated with the IN alert state (0.92 events/patient-year versus 0.03 events/patient-year in the OUT of alert state). The hazard ratio in the IN/OUT of alert state comparison was (hazard ratio, 24.53 [95% CI, 8.55–70.38], P
- Published
- 2021
28. Magnitude of QRS duration reduction after biventricular pacing identifies responders to cardiac resynchronization therapy
- Author
-
Attilio Pierantozzi, Antonio D'Onofrio, Laura Ajello, G. Savarese, Patrizia Pepi, Pietro Palmisano, Giuseppe Coppola, Antonio De Simone, Giampiero Maglia, Giosuè Mascioli, Giuseppe Arena, Giuseppe Stabile, T. Giovannini, Patrizia Carità, Luigi Padeletti, Gianfranco Ciaramitaro, Salvatore Ivan Caico, Domenico Pecora, Maurizio Malacrida, Antonio Rapacciuolo, Egle Corrado, Cinzia Nugara, Massimiliano Marini, Coppola, Giuseppe, Ciaramitaro, Gianfranco, Stabile, Giuseppe, DOnofrio, Antonio, Palmisano, Pietro, Carità, Patrizia, Mascioli, Giosuè, Pecora, Domenico, De Simone, Antonio, Marini, Massimiliano, Rapacciuolo, Antonio, Savarese, Gianluca, Maglia, Giampiero, Pepi, Patrizia, Padeletti, Luigi, Pierantozzi, Attilio, Arena, Giuseppe, Giovannini, Tiziana, Caico, Salvatore Ivan, Nugara, Cinzia, Ajello, Laura, Malacrida, Maurizio, Corrado, Egle, and Donofrio, Antonio
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Cardiac resynchronization therapy ,Heart failure ,030204 cardiovascular system & hematology ,Follow-Up Studie ,Cohort Studies ,03 medical and health sciences ,QRS complex ,Reverse remodeling ,0302 clinical medicine ,Heart Rate ,Cardiovascular Disease ,Internal medicine ,medicine ,Humans ,Pacing ,In patient ,Prospective Studies ,cardiovascular diseases ,030212 general & internal medicine ,Aged ,Ventricular Remodeling ,ECG ,business.industry ,Hazard ratio ,Area under the curve ,Middle Aged ,medicine.disease ,Survival Rate ,Prospective Studie ,Cardiovascular Diseases ,cardiovascular system ,Cardiology ,Female ,Cohort Studie ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,Human - Abstract
Background Several studies have investigated the association between native QRS duration (QRSd) or QRS narrowing and response to biventricular pacing. However, their results have been conflicting. The aim of our study was to determine the association between the relative change in QRS narrowing index (QI) and clinical outcome and prognosis in patients who undergo cardiac resynchronization therapy (CRT) implantation. Methods and results We included 311 patients in whom a CRT device was implanted in accordance with current guidelines for CRT. On implantation, the native QRS, the QRSd and the QI during CRT were measured. After 6months, 220 (71%) patients showed a 10% reduction in LVESV. The median [25th–75th] QI was 14.3% [7.2–21.4] and was significantly related to reverse remodeling (r=+0.22; 95%CI: 0.11–0.32, p=0.0001). The cut-off value of QI that best predicted LV reverse remodeling after 6months of CRT was 12.5% (sensitivity=63.6%, specificity=57.1%, area under the curve=0.633, p=0.0002). The time to the event death or cardiovascular hospitalization was significantly longer among patients with QI>12.5% (log-rank test, p=0.0155), with a hazard ratio (HR) of 0.3 [95%CI: 0.11–0.78]. In the multivariate regression model adjusted for baseline parameters, a 10% increment in QI (HR=0.61[0.44–0.83], p=0.002) remained significantly associated with CRT response. Conclusions Patients with a larger decrease in QRSd after CRT initiation showed greater echocardiographic reverse remodeling and better outcome from death or cardiovascular hospitalization. QI is an easy-to-measure variable that could be used to predict CRT response at the time of pacing site selection or pacing configuration programming.
- Published
- 2016
- Full Text
- View/download PDF
29. 3290The VALID-CRT risk score reliably predicts outcome after cardiac resynchronization therapy in an real-world population
- Author
-
Anna Ferraro, Giuseppe Stabile, A. Spotti, G. Savarese, Quintino Parisi, Domenico Pecora, C La Greca, Albino Reggiani, Emanuele Bertaglia, Pietro Palmisano, S. Badolati, Giampiero Maglia, Francesco Solimene, Maurizio Malacrida, and T. Giovannini
- Subjects
medicine.medical_specialty ,Framingham Risk Score ,business.industry ,medicine.medical_treatment ,Emergency medicine ,medicine ,Cardiac resynchronization therapy ,World population ,Cardiology and Cardiovascular Medicine ,business ,Outcome (game theory) - Published
- 2018
- Full Text
- View/download PDF
30. Definition, epidemiology, and burden of disease: HFpEF
- Author
-
G. Savarese and Lars H. Lund
- Subjects
Burden of disease ,medicine.medical_specialty ,business.industry ,Epidemiology ,Medicine ,business ,Intensive care medicine - Abstract
Heart failure with preserved ejection fraction (HFpEF) is a global pandemic, affecting half of the heart failure population and with an incidence and prevalence expected to increase further with an ageing population. With no therapy to reduce morbidity or mortality, HFpEF has been defined as the single largest unmet need in cardiovascular medicine. As compared with heart failure with reduced ejection fraction (HFrEF), patients with HFpEF are more likely to be older and female, to have a higher prevalence of cardiovascular risk factors (i.e. obesity, hypertension, and diabetes), other cardiovascular co-morbidities (i.e. atrial fibrillation and valvular disease) and non-cardiovascular co-morbidities (i.e. anaemia, chronic pulmonary disease, and chronic kidney disease), but a lower prevalence of ischaemic heart disease. In non-selective cohorts and registries, crude but not adjusted mortality is higher in HFpEF vs. HFrEF, with risk of cardiovascular events lower in HFpEF, especially in clinical trial populations. A novel category, heart failure with mid-range ejection fraction (HFmrEF) has been introduced for an ejection fraction in the 40–49% range, to emphasize that this range is not normal but also has no evidence-based interventions. HFmrEF appears similar to HFrEF with regard to ischaemic heart disease prevalence and outcomes, but is intermediate between HFpEF and HFrEF in many other aspects.
- Published
- 2018
- Full Text
- View/download PDF
31. Ivabradine in Heart Failure
- Author
-
Jonathan G. Howlett, G. Savarese, Ulf Dahlström, Justin A. Ezekowitz, Michael Fu, Debraj Das, and Lars H. Lund
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Adrenergic beta-Antagonists ,Population ,Eligibility Determination ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Heart Rate ,Internal medicine ,Heart rate ,medicine ,Humans ,Ivabradine ,Registries ,030212 general & internal medicine ,education ,Aged ,Aged, 80 and over ,Sweden ,Clinical Trials as Topic ,education.field_of_study ,business.industry ,Patient Selection ,Cardiovascular Agents ,Stroke Volume ,Benzazepines ,Middle Aged ,medicine.disease ,Clinical trial ,Treatment Outcome ,Heart failure ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Heart Failure, Systolic ,medicine.drug - Abstract
Background: The sinus node inhibitor ivabradine was approved for patients with heart failure (HF) after the ivabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial]) trial. Our objective was to characterize the proportion of patients with HF eligible for ivabradine and the representativeness of the SHIFT trial enrollees compared with those in the Swedish Heart Failure Registry. Methods and Results: We examined 26 404 patients with clinical HF from the Swedish Heart Failure Registry and divided them into SHIFT type (left ventricular ejection fraction P P =0.421) were receiving selected β-blockers, only 58.8% and 67.3% ( P 50% of target dose. From those patients who had repeated visits within 6 months (n=5420) and 1 year (n=6840), respectively, 10.2% (n=555) and 10.6% (n=724) of SHIFT-type patients became ineligible, 77.3% (n=4188) and 77.3% (n=5287) remained ineligible, and 4.6% (n=252) and 4.9% (n=335) of non-SHIFT–type patients became eligible for initiation of ivabradine. Conclusions: From the Swedish Heart Failure Registry, 14.2% of patients with HF were eligible for ivabradine. These patients more commonly were not receiving target β-blocker dose. Over time, a minority of patients became ineligible and an even smaller minority became eligible.
- Published
- 2017
- Full Text
- View/download PDF
32. 2058Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction
- Author
-
Camilla Hage, G. Savarese, Lars Lund, Giuseppe M.C. Rosano, Ulf Dahlström, and Nicola Orsini
- Subjects
medicine.medical_specialty ,Ejection fraction ,business.industry ,Heart failure ,Internal medicine ,medicine ,Cardiology ,N terminal pro b type natriuretic peptide ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business - Published
- 2017
- Full Text
- View/download PDF
33. P5474All-cause mortality in cardiac resynchronization therapy is predicted by the degree of LV reverse remodeling at mid-term follow-up
- Author
-
F. Iuele, Maurizio Malacrida, Antonio D'Onofrio, Giuseppe Arena, Luca Checchi, Francesco Solimene, G. Savarese, Massimiliano Marini, M. Pasqualini, Attilio Pierantozzi, Quintino Parisi, Antonio Rapacciuolo, G.L. Botto, Albino Reggiani, and Giuseppe Stabile
- Subjects
Mid term follow up ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Internal medicine ,Cardiac resynchronization therapy ,Cardiology ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Reverse remodeling ,Degree (temperature) - Published
- 2017
- Full Text
- View/download PDF
34. P5486Predictors of mortality in CRT patients: results from a large real-world population
- Author
-
Antonio D'Onofrio, A De Simone, Patrizia Pepi, G. Savarese, Massimiliano Marini, Maurizio Malacrida, Emanuele Bertaglia, Domenico Pecora, Matteo Santamaria, Pietro Palmisano, Giuseppe Arena, Si. Caico, G.L. Botto, Giuseppe Stabile, and Paolo Pieragnoli
- Subjects
business.industry ,Medicine ,World population ,Cardiology and Cardiovascular Medicine ,business ,Demography - Published
- 2017
- Full Text
- View/download PDF
35. P5485Effective non-apical left ventricular pacing with quadripolar leads for cardiac resynchronization therapy: a multicenter study
- Author
-
C. Gerosa, Luca Santini, G. B. Forleo, Domenico Sergi, Stefano Donzelli, G. Panattoni, G. Mangone, Vincenzo Schillaci, S. Badolati, G. Savarese, Francesco Solimene, Sergio Valsecchi, Massimo Sassara, and G. Covino
- Subjects
medicine.medical_specialty ,Multicenter study ,business.industry ,medicine.medical_treatment ,Internal medicine ,Cardiac resynchronization therapy ,medicine ,Cardiology ,Ventricular pacing ,Cardiology and Cardiovascular Medicine ,business - Published
- 2017
- Full Text
- View/download PDF
36. 1014Impact of CHA2DS2-VASc and HAS-BLED SCORES on oral anticoagulant use and outcomes in patients with atrial fibrillation and concomitant heart failure: an analysis of 22,055 patients from the SwedeHF
- Author
-
Ulf Dahlström, Mårten Rosenqvist, Lars Lund, G. Savarese, and Leif Friberg
- Subjects
HAS-BLED ,medicine.medical_specialty ,business.industry ,Atrial fibrillation ,medicine.disease ,Concomitant ,Heart failure ,Internal medicine ,Oral anticoagulant ,Cardiology ,Medicine ,In patient ,Cardiology and Cardiovascular Medicine ,business - Published
- 2017
- Full Text
- View/download PDF
37. 267The VALID-CRT risk score reliably predicts outcome after cardiac resynchronization therapy in an real-world population
- Author
-
Antonella Cecchetto, S. Badolati, Giuseppe Stabile, Pietro Palmisano, T. Giovannini, A. Spotti, Quintino Parisi, Anna Baritussio, Emanuele Bertaglia, G. Savarese, Albino Reggiani, Giampiero Maglia, Francesco Solimene, Maurizio Malacrida, and Anna Ferraro
- Subjects
medicine.medical_specialty ,Framingham Risk Score ,business.industry ,Physiology (medical) ,medicine.medical_treatment ,Emergency medicine ,medicine ,Cardiac resynchronization therapy ,World population ,Cardiology and Cardiovascular Medicine ,business ,Outcome (game theory) - Published
- 2018
- Full Text
- View/download PDF
38. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
- Author
-
Trillsch, F. Mahner, S. Hilpert, F. Davies, L. García-Martínez, E. Kristensen, G. Savarese, A. Vuylsteke, P. Los, M. Zagouri, F. Gladieff, L. Sehouli, J. Khoon Lee, C. Gebski, V. Pujade-Lauraine, E.
- Subjects
education - Abstract
Background: Progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial. We explored treatment outcomes according to primary platinum resistance (PPR) versus secondary platinum resistance (SPR). Patients and methods: Patients were categorized as PPR (disease progression
- Published
- 2016
39. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction
- Author
-
Nicola Orsini, Pasquale Perrone-Filardi, Lars H. Lund, Camilla Hage, G. Savarese, Giuseppe M.C. Rosano, Ulf Dahlström, Savarese, Gianluigi, Hage, Camilla, Orsini, Nicola, Dahlström, Ulf, PERRONE FILARDI, Pasquale, Rosano, Giuseppe M. C, and Lund, Lars H.
- Subjects
Male ,heart failure with preserved ejection fraction ,medicine.medical_specialty ,medicine.drug_class ,030204 cardiovascular system & hematology ,registry ,Efficacy ,03 medical and health sciences ,0302 clinical medicine ,Cause of Death ,Internal medicine ,Natriuretic Peptide, Brain ,medicine ,Natriuretic peptide ,Humans ,Prospective Studies ,Registries ,030212 general & internal medicine ,Mortality ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,Heart Failure ,Sweden ,Ejection fraction ,business.industry ,Hazard ratio ,Stroke Volume ,Middle Aged ,Prognosis ,medicine.disease ,Peptide Fragments ,Confidence interval ,Hospitalization ,Heart failure ,heart failure with mid-range ejection fraction ,Cardiology ,Female ,N-terminal pro–B-type natriuretic peptide ,Cardiology and Cardiovascular Medicine ,business ,Heart failure with preserved ejection fraction ,N-terminal pro-Brain Natriuretic Peptide ,prognosi - Abstract
Background— In heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF), feasible surrogate end points are needed for phase II trials. The aim was to assess whether a reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP) is associated with improved mortality/morbidity in an unselected population of HFmrEF and HFpEF patients. Methods and Results— In the Swedish Heart Failure Registry, HFmrEF (EF=40%–49%) and HFpEF (EF≥50%) patients reporting at least 2 consecutive outpatient NT-proBNP assessments were prospectively studied. Associations between reduction in NT-proBNP and overall mortality, HF hospitalization, and their composite were assessed by multivariable Cox regressions, with NT-proBNP changes modeled as binary (decrease/increase) or quantitative predictor by restricted cubic splines. In 650 patients, at a median of 7 months between the 2 measurements of NT-proBNP and over a median follow-up of 1.65 years, 361 patients (55%) showed a reduction and 289 patients (45%) an increase in NT-proBNP. Change in NT-proBNP was associated with risk of outcomes. Fifty-seven patients (16%) who decreased their NT-proBNP versus 78 patients (27%) who increased it died from any cause (adjusted hazard ratio=0.53; 95% confidence interval=0.36–0.77), 61 (17%) versus 86 (30%) were hospitalized for HF (hazard ratio=0.41; 95% confidence interval=0.29–0.60), and 96 (27%) versus 125 (43%) reported the composite outcome (hazard ratio=0.46; 95% confidence interval=0.34–0.62). These findings were replicated in HFmrEF and HFpEF separately. Conclusions— In HFmrEF and HFpEF during routine care, decreases in NT-proBNP were associated with improved mortality and morbidity. Studies to determine whether NT-proBNP changes in response to therapy predict drug efficacy are needed.
- Published
- 2016
40. P974Effective non-apical left ventricular pacing with quadripolar leads for cardiac resynchronization therapy: a multicenter study
- Author
-
Stefano Donzelli, Domenico Sergi, G. Savarese, Luca Santini, Sergio Valsecchi, G. Covino, Gb. Forleo, Vincenzo Schillaci, Massimo Sassara, S. Badolati, Mariolina Lovecchio, Germana Panattoni, C. Gerosa, Francesco Solimene, and F. Picariello
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cardiac resynchronization therapy ,030204 cardiovascular system & hematology ,Ventricular pacing ,03 medical and health sciences ,0302 clinical medicine ,Multicenter study ,Physiology (medical) ,Internal medicine ,medicine ,Cardiology ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2017
- Full Text
- View/download PDF
41. P1009Predictors of mortality in CRT patients: results from a large real-world population
- Author
-
Si. Caico, A De Simone, G.L. Botto, Patrizia Pepi, F. Guarracini, Matteo Santamaria, Maurizio Malacrida, Giuseppe Stabile, Antonio D'Onofrio, Paolo Pieragnoli, Domenico Pecora, Pietro Palmisano, G. Savarese, Giuseppe Arena, and Emanuele Bertaglia
- Subjects
business.industry ,Physiology (medical) ,Medicine ,World population ,Cardiology and Cardiovascular Medicine ,business ,Demography - Published
- 2017
- Full Text
- View/download PDF
42. Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area
- Author
-
M. Wang, G. Yan, W. Yue, C. Siu, H. Tse, A. Perperidis, D. Cusack, A. White, T. Macgillivray, W. Mcdicken, T. Anderson, V. Ryabov, V. Shurupov, T. Suslova, V. Markov, N. Elmstedt, K. Ferm Widlund, B. Lind, L.-A. Brodin, M. Westgren, F. Mantovani, A. Barbieri, F. Bursi, C. Valenti, M. Quaglia, M. Modena, D. Peluso, D. Muraru, L. Dal Bianco, M. Beraldo, E. Solda', M. Tuveri, U. Cucchini, A. Al Mamary, L. Badano, S. Iliceto, A. Goncalves, C. Almeria, P. Marcos-Alberca, G. Feltes, R. Hernandez-Antolin, H. Rodriguez, L. Maroto, J. Silva Cardoso, C. Macaya, J. Zamorano, S. Squarciotta, F. Innocenti, A. Guzzo, S. Bianchi, D. Lazzeretti, E. De Villa, S. Vicidomini, B. Del Taglia, C. Donnini, R. Pini, C. Mennie, A. M. Salmasi, V. Kutyifa, V. Nagy, E. Edes, A. Apor, B. Merkely, S. Nyrnes, L. Lovstakken, H. Torp, B. Haugen, K. Said, A. Shehata, Z. Ashour, S. El-Tobgy, M. Cameli, E. Bigio, M. Lisi, F. Righini, F. Franchi, S. Scolletta, S. Mondillo, E. Gayat, L. Weinert, C. Yodwut, V. Mor-Avi, R. Lang, N. Hrynchyshyn, N. Kachenoura, B. Diebold, R. Khedim, M. Senesi, A. Redheuil, E. Mousseaux, L. Perdrix, S. Yurdakul, V. Erdemir, Y. Tayyareci, K. Memic, O. Yildirimturk, V. Aytekin, M. Gurel, S. Aytekin, L. Gargani, C. Fernandez Cimadevilla, S. La Falce, P. Landi, E. Picano, R. Sicari, M. K. Smedsrud, J. Gravning, C. Eek, L. Morkrid, H. Skulstad, L. Aaberge, B. Bendz, J. Kjekshus, T. Edvardsen, G. Bajraktari, V. Hyseni, B. Morina, A. Batalli, R. Tafarshiku, R. Olloni, M. Henein, O. Mjolstad, S. Snare, L. Folkvord, F. Helland, O. Haraldseth, A. Grimsmo, M. Berry, O. Zaghden, J. Nahum, L. Macron, O. Lairez, T. Damy, A. Bensaid, J. Dubois Rande, P. Gueret, P. Lim, N. Nciri, Z. Issaoui, C. Tlili, I. Wanes, H. Foudhil, F. Dachraoui, J. Grapsa, D. Dawson, P. Nihoyannopoulos, L. Gianturco, M. Turiel, F. Atzeni, P. Sarzi-Puttini, D. Stella, L. Donato, L. Tomasoni, P. Jung, M. Mueller, T. Huber, G. Sevilmis, F. Kroetz, H. Sohn, V. Panoulas, A. Bratsas, R. Raso, G. Tartarisco, G. Pioggia, P. Gargiulo, M. Petretta, A. Cuocolo, M. Prastaro, C. D'amore, E. Vassallo, G. Savarese, C. Marciano, S. Paolillo, P. Perrone Filardi, C. Aggeli, I. Felekos, G. Roussakis, E. Poulidakis, P. Pietri, K. Toutouzas, C. Stefanadis, A. Kaladaridis, I. Skaltsiotis, G. Kottis, D. Bramos, D. Takos, I. Matthaios, I. Agrios, E. Papadopoulou, S. Moulopoulos, S. Toumanidis, P. Carrilho-Ferreira, N. Cortez-Dias, C. Jorge, D. Silva, J. Silva Marques, R. Placido, L. Santos, S. Ribeiro, M. Fiuza, F. Pinto, V. Stoickov, S. Ilic, M. Deljanin Ilic, W. Kim, J. Woo, J. Bae, K. Kim, M. Descalzo, J. Rodriguez, S. Moral, I. Otaegui, P. Mahia, L. Garcia Del Blanco, T. Gonzalez Alujas, J. Figueras, A. Evangelista, D. Garcia-Dorado, M. Takeuchi, K. Kaku, K. Otani, M. Iwataki, H. Kuwaki, N. Haruki, H. Yoshitani, Y. Otsuji, M. Kukucka, M. Pasic, A. Unbehaun, S. Dreysse, A. Mladenow, H. Kuppe, R. Hetzer, N. Rajamannan, A. Tanrikulu, L. Kristiansson, S. Gustafsson, K. Lindmark, M. Y. Henein, C. Evdoridis, P. Stougiannos, M. Thomopoulos, M. Fosteris, P. Spanos, G. Sionis, D. Giatsios, A. Paschalis, C. Sakellaris, A. Trikas, Z. Y. Yong, K. Boerlage-Van Dijk, K. Koch, M. Vis, B. Bouma, J. Piek, J. Baan, L. Abid, Z. Frikha, K. Makni, N. Maazoun, D. Abid, M. Hentati, S. Kammoun, P. Barbier, A. Staron, C. Cefalu', G. Berna, P. Gripari, D. Andreini, G. Pontone, M. Pepi, L. Ring, B. Rana, S. Ho, F. Wells, A. Dogan, O. Karaca, G. Guler, E. Guler, H. Gunes, E. Alizade, H. Agus, G. Gol, O. Esen, A. Esen, M. Turkmen, E. Agricola, G. Ingallina, M. Ancona, S. Maggio, M. Slavich, V. Tufaro, M. Oppizzi, A. Margonato, C. Orsborne, B. Irwin, K. Pearce, S. Ray, C. Garcia Alonso, N. Vallejo, C. Labata, J. Lopez Ayerbe, A. Teis, E. Ferrer, R. Nunez Aragon, F. Gual, M. Pedro Botet, A. Bayes Genis, C. M. Santos, M. Carvalho, M. Andrade, H. Dores, S. Madeira, G. Cardoso, A. Ventosa, C. Aguiar, R. Ribeiras, M. Mendes, M. Petrovic, G. Milasinovic, B. Vujisic-Tesic, I. Nedeljkovic, D. Zamaklar-Trifunovic, I. Petrovic, G. Draganic, M. Banovic, M. Boricic, H. Villarraga, C. Molini-Griggs Bs, P. Silen-Rivera Bs, B. Payne Mph Ms, Y. Koshino Md Phd, J. Hsiao Md, V. Monivas Palomero, S. Mingo Santos, C. Mitroi, I. Garcia Lunar, P. Garcia Pavia, V. Castro Urda, J. Toquero, J. Gonzalez Mirelis, M. Cavero Gibanel, I. Fernandez Lozano, Z. Oko-Sarnowska, H. Wachowiak-Baszynska, A. Katarzynska-Szymanska, O. Trojnarska, S. Grajek, D. Bellavia, P. Pellikka, A. Dispenzieri, J. K. Oh, V. Polizzi, F. Pitrolo, F. Musumeci, F. Miller, R. Ancona, S. Comenale Pinto, P. Caso, S. Severino, C. Cavallaro, F. Vecchione, A. D'onofrio, R. Calabro', A. M. Maceira Gonzalez, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch, J. Cosin-Aguilar, B. Pinamonti, A. Iorio, M. Bobbo, M. Merlo, G. Barbati, L. Massa, G. Faganello, A. Di Lenarda, G. F. Sinagra, T. Ishizu, Y. Seo, M. Enomoto, Y. Kameda, N. Ishibashi, M. Inoue, K. Aonuma, A. Saleh, A. Matsumori, H. Negm, H. Fouad, A. Onsy, E. Hamodraka, I. Paraskevaidis, M. Kallistratos, V. Lezos, T. Zamfir, C. Manetos, D. Mavropoulos, L. Poulimenos, D. Kremastinos, A. Manolis, R. Citro, F. Rigo, Q. Ciampi, M. Patella, G. Provenza, C. Zito, E. Tagliamonte, F. Rotondi, F. Silvestri, E. Bossone, P. Beltran Correas, C. Gutierrez Landaluce, M. Gomez Bueno, J. Segovia Cubero, C. Beladan, F. Matei, B. Popescu, A. Calin, M. Rosca, A. Boanta, R. Enache, O. Savu, C. Usurelu, C. Ginghina, A. O. Ciobanu, R. Dulgheru, S. Magda, R. Dragoi, M. Florescu, D. Vinereanu, S. Robalo Martins, C. Calisto, S. Goncalves, I. Barrigoto, J. Carvalho De Sousa, A. Almeida, A. Nunes Diogo, L. Sargento, M. Satendra, C. Sousa, N. Lousada, R. Palma Reis, V. Schiano Lomoriello, R. Esposito, A. Santoro, R. Raia, P. Schiattarella, E. Dores, M. Galderisi, N. Mansencal, V. Caille, A. Dupland, S. Perrot, K. Bouferrache, A. Vieillard-Baron, R. Jouffroy, P. Moceri, E. Liodakis, M. Gatzoulis, W. Li, K. Dimopoulos, M. Sadron, P. E. Seguela, B. Arnaudis, Y. Dulac, T. Cognet, P. Acar, Y. Shiina, H. Uemura, K. Kupczynska, J. Kasprzak, B. Michalski, P. Lipiec, V. Carvalho, A. M. G. Almeida, C. David, J. Marques, P. Ferreira, M. Amaro, P. Costa, A. Diogo, V. Tritakis, I. Ikonomidis, J. Lekakis, S. Tzortzis, N. Kadoglou, I. Papadakis, P. Trivilou, C. Koukoulis, M. Anastasiou-Nana, T. Bombardini, S. Gherardi, G. Arpesella, M. Maccherini, W. Serra, G. Magnani, R. Del Bene, E. Pasanisi, U. Startari, L. Panchetti, A. Rossi, M. Piacenti, M. Morales, I. El Hajjaji, R. El Mahmoud, F. Digne, O. Dubourg, G. Agoston, A. Moreo, L. Pratali, A. Moggi Pignone, A. Pavellini, M. Doveri, F. Musca, A. Varga, F. Faita, S. Rimoldi, C. Sartori, Y. Alleman, C. Salinas Salmon, M. Villena, U. Scherrer, R. Baptista, S. Serra, G. Castro, R. Martins, M. Salvador, P. Monteiro, J. Silva, L. Szudi, A. Temesvary, B. Fekete, I. Kassai, L. Szekely, S. S. Abdel Moneim, M. Martinez, S. Mankad, M. Bernier, A. Dhoble, K. Chandrasekaran, J. Oh, S. Mulvagh, G. R. Hong, J. Y. Kim, S. C. Lee, S. H. Choi, I. S. Sohn, H. S. Seo, J. H. Choi, K. I. Cho, S. J. Yoon, S. J. Lim, P. Wejner-Mik, J. Kusmierek, A. Plachcinska, R. Szuminski, S. Stoebe, A. Tarr, T. Trache, A. Hagendorff, C. Jenkins, H. Kuhl, H. Nesser, T. Marwick, A. Franke, J. Niel, L. Sugeng, S. Soderberg, P. Lindqvist, J. Necas, S. Kovalova, S. K. Saha, A. Kiotsekoglou, R. Toole, S. Govind, A. Gopal, M.-S. Amzulescu, A. Florian, J. Bogaert, S. Janssens, J. Voigt, V. Parisi, M. Losi, L. Parrella, C. Contaldi, E. Chiacchio, A. Caputi, A. Scatteia, A. Buonauro, S. Betocchi, R. Rimbas, S. Mihaila, M. Caputo, R. Navarri, P. Innelli, R. Urselli, E. Capati, P. Ballo, F. Furiozzi, R. Favilli, R. Lindquist, A. Miller, C. Reece, P. O'leary, F. Cetta, B. W. Eidem, M. Cikes, H. Gasparovic, B. Bijnens, V. Velagic, T. Kopjar, B. Biocina, D. Milicic, A. Ta-Shma, A. Nir, Z. Perles, S. Gavri, J. Golender, A. Rein, G. Pinnacchio, L. Barone, I. Battipaglia, A. Cosenza, L. Marinaccio, I. Coviello, G. Scalone, A. Sestito, G. Lanza, F. Crea, S. Cakal, E. Eroglu, B. Ozkan, S. Kulahcioglu, M. Bulut, A. Koyuncu, G. Acar, G. Alici, C. Dundar, F. Labombarda, E. Zangl, A. Pellissier, D. Bougle, P. Maragnes, P. Milliez, E. Saloux, S. Lagoudakou, E. Gialafos, A. Tsokanis, A. Nagy, T. Kovats, H. Vago, A. Toth, B. Sax, A. Kovacs, M. F. Elnoamany, H. Badran, I. Abdelfattah, T. Khalil, M. Salama, T. Butz, C. Taubenberger, F. Thangarajah, A. Meissner, M. Van Bracht, M. Prull, H. Yeni, G. Plehn, H. Trappe, R. Rydman, D. Bone, M. Alam, K. Caidahl, F. Larsen, Z. Gasior, Z. Tabor, P. Sengupta, D. Liu, M. Niemann, K. Hu, S. Herrmann, S. Stoerk, C. Morbach, S. Knop, W. Voelker, G. Ertl, F. Weidemann, P. Cawley, C. Hamilton-Craig, L. Mitsumori, J. Maki, C. Otto, M. Astrom Aneq, E. Nylander, T. Ebbers, J. Engvall, P. Arvanitis, F. Flachskampf, O. Duvernoy, F. De Torres Alba, S. Valbuena Lopez, G. Guzman Martinez, J. Gomez De Diego, J. Rey Blas, E. Armada Romero, E. Lopez De Sa, M. Moreno Yanguela, J. Lopez Sendon, N. Trikalinos, G. Siasos, A. Aggeli, A. Tomaszewski, A. Kutarski, M. Tomaszewski, O. Vriz, C. Driussi, M. Bettio, D. Pavan, F. Antonini Canterin, A. Doltra Magarolas, J. Fernandez-Armenta, E. Silva, N. Solanes, M. Rigol, A. Barcelo, L. Mont, A. Berruezo, J. Brugada, M. Sitges, F. L. Ciciarello, S. Mandolesi, F. Fedele, L. Agati, A. Marceca, S. Rhee, S. Shin, S. Kim, K. Yun, N. Yoo, N. Kim, S. Oh, J. Jeong, and N. Alabdulkarim
- Subjects
education.field_of_study ,medicine.medical_specialty ,business.industry ,Multiple sclerosis ,Population ,Hemodynamics ,General Medicine ,Cerebro ,medicine.disease ,Internal medicine ,Cardiology ,Medicine ,Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine ,education ,business - Published
- 2011
- Full Text
- View/download PDF
43. Abstracts
- Author
-
V. Dunet, A. Dabiri, G. Allenbach, A. Goyeneche Achigar, B. Waeber, F. Feihl, R. Heinzer, J. O. Prior, J. E. Van Velzen, J. D. Schuijf, F. R. De Graaf, M. A. De Graaf, M. J. Schalij, L. J. Kroft, A. De Roos, J. W. Jukema, E. E. Van Der Wall, J. J. Bax, E. Lankinen, A. Saraste, T. Noponen, R. Klen, M. Teras, T. Kokki, S. Kajander, M. Pietila, H. Ukkonen, J. Knuuti, A. P. Pazhenkottil, R. N. Nkoulou, J. R. Ghadri, B. A. Herzog, R. R. Buechel, S. M. Kuest, M. Wolfrum, O. Gaemperli, L. Husmann, P. A. Kaufmann, D. Andreini, G. Pontone, S. Mushtaq, L. Antonioli, E. Bertella, A. Formenti, S. Cortinovis, G. Ballerini, C. Fiorentini, M. Pepi, A. S. Koh, J. S. Flores, F. Y. J. Keng, R. S. Tan, T. S. J. Chua, A. D. Annoni, G. Tamborini, M. Fusari, A. L. Bartorelli, S. H. Ewe, A. C. T. Ng, V. Delgado, J. Schuijf, F. Van Der Kley, A. Colli, A. De Weger, N. A. Marsan, K. H. Yiu, A. C. Ng, S. A. J. Timmer, P. Knaapen, T. Germans, P. A. Dijkmans, M. Lubberink, J. M. Ten Berg, F. J. Ten Cate, I. K. Russel, A. A. Lammertsma, A. C. Van Rossum, Y. Y. Wong, G. Ruiter, P. Raijmakers, W. J. Van Der Laarse, N. Westerhof, A. Vonk-Noordegraaf, G. Youssef, E. Leung, G. Wisenberg, C. Marriot, K. Williams, J. Etele, R. A. Dekemp, J. Dasilva, D. Birnie, R. S. B. Beanlands, R. C. Thompson, A. H. Allam, L. S. Wann, A. H. Nureldin, G. Adelmaksoub, I. Badr, M. L. Sutherland, J. D. Sutherland, M. I. Miyamoto, G. S. Thomas, H. J. Harms, S. De Haan, M. C. Huisman, R. C. Schuit, A. D. Windhorst, C. Allaart, A. J. Einstein, T. Khawaja, C. Greer, A. Chokshi, M. Jones, K. Schaefle, K. Bhatia, D. Shimbo, P. C. Schulze, A. Srivastava, R. Chettiar, J. Moody, C. Weyman, D. Natale, W. Bruni, Y. Liu, E. Ficaro, A. J. Sinusas, A. Peix, E. Batista, L. O. Cabrera, K. Padron, L. Rodriguez, B. Sainz, V. Mendoza, R. Carrillo, Y. Fernandez, E. Mena, A. Naum, T. Bach-Gansmo, N. Kleven-Madsen, M. Biermann, B. Johnsen, J. Aase Husby, S. Rotevatn, J. E. Nordrehaug, J. Schaap, R. M. Kauling, M. C. Post, B. J. W. M. Rensing, J. F. Verzijlbergen, J. Sanchez, G. Giamouzis, N. Tziolas, P. Georgoulias, G. Karayannis, A. Chamaidi, N. Zavos, K. Koutrakis, G. Sitafidis, J. Skoularigis, F. Triposkiadis, S. Radovanovic, A. Djokovic, D. V. Simic, M. Krotin, A. Savic-Radojevic, M. Pljesa-Ercegovac, M. Zdravkovic, J. Saponjski, S. Jelic, T. Simic, R. Eckardt, B. J. Kjeldsen, L. I. Andersen, T. Haghfelt, P. Grupe, A. Johansen, B. Hesse, H. Pena, G. Cantinho, M. Wilk, Y. Srour, F. Godinho, N. Zafrir, A. Gutstein, I. Mats, A. Battler, A. Solodky, E. Sari, N. Singh, A. Vara, A. M. Peters, A. De Belder, S. Nair, N. Ryan, R. James, S. Dizdarevic, G. Depuey, M. Friedman, R. Wray, R. Old, H. Babla, B. Chuanyong, J. Maddahi, E. Tragardh Johansson, K. Sjostrand, L. Edenbrandt, S. Aguade-Bruix, G. Cuberas-Borros, M. N. Pizzi, M. Sabate-Fernandez, G. De Leon, D. Garcia-Dorado, J. Castell-Conesa, J. Candell-Riera, D. Casset-Senon, M. Edjlali-Goujon, D. Alison, A. Delhommais, P. Cosnay, C. S. Low, A. Notghi, J. O'brien, A. C. Tweddel, N. Bingham, P. O Neil, M. Harbinson, O. Lindner, W. Burchert, M. Schaefers, C. Marcassa, R. Campini, P. Calza, O. Zoccarato, A. Kisko, J. Kmec, M. Babcak, M. Vereb, M. Vytykacova, J. Cencarik, P. Gazdic, J. Stasko, A. Abreu, E. Pereira, L. Oliveira, P. Colarinha, V. Veloso, I. Enriksson, G. Proenca, P. Delgado, L. Rosario, J. Sequeira, I. Kosa, I. Vassanyi, C. S. Egyed, G. Y. Kozmann, S. Morita, M. Nanasato, I. Nanbu, Y. Yoshida, H. Hirayama, A. Allam, A. Sharef, I. Shawky, M. Farid, M. Mouden, J. P. Ottervanger, J. R. Timmer, M. J. De Boer, S. Reiffers, P. L. Jager, S. Knollema, G. M. Nasr, M. Mohy Eldin, M. Ragheb, I. Casans-Tormo, R. Diaz-Exposito, F. J. Hurtado-Mauricio, R. Ruano, M. Diego, F. Gomez-Caminero, C. Albarran, A. Martin De Arriba, A. Rosero, R. Lopez, C. Martin Luengo, J. R. Garcia-Talavera, I. E. K. Laitinen, M. Rudelius, E. Weidl, G. Henriksen, H. J. Wester, M. Schwaiger, X. B. Pan, T. Schindler, A. Quercioli, H. Zaidi, O. Ratib, J. M. Declerck, E. Alexanderson Rosas, R. Jacome, M. Jimenez-Santos, E. Romero, M. A. Pena-Cabral, A. Meave, J. Gonzalez, F. Rouzet, L. Bachelet, J. M. Alsac, M. Suzuki, L. Louedec, A. Petiet, F. Chaubet, D. Letourneur, J. B. Michel, D. Le Guludec, A. Aktas, A. Cinar, G. Yaman, T. Bahceci, K. Kavak, A. Gencoglu, A. Jimenez-Heffernan, E. Sanchez De Mora, J. Lopez-Martin, R. Lopez-Aguilar, C. Ramos, C. Salgado, A. Ortega, C. Sanchez-Gonzalez, J. Roa, A. Tobaruela, S. V. Nesterov, O. Turta, M. Maki, C. Han, D. Daou, M. Tawileh, S. O. Chamouine, C. Coaguila, E. Mariscal-Labrador, N. Kisiel-Gonzalez, P. De Araujo Goncalves, P. J. Sousa, H. Marques, J. O'neill, J. Pisco, R. Cale, J. Brito, A. Gaspar, F. P. Machado, J. Roquette, M. Martinez, G. Melendez, E. Kimura, J. M. Ochoa, A. M. Alessio, A. Patel, R. Lautamaki, F. M. Bengel, J. B. Bassingthwaighte, J. H. Caldwell, K. Rahbar, H. Seifarth, M. Schafers, L. Stegger, T. Spieker, A. Hoffmeier, D. Maintz, H. Scheld, O. Schober, M. Weckesser, H. Aoki, I. Matsunari, K. Kajinami, M. Martin Fernandez, M. Barreiro Perez, O. V. Fernandez Cimadevilla, D. Leon Duran, E. Velasco Alonso, J. P. Florez Munoz, L. H. Luyando, C. Templin, C. E. Veltman, J. H. C. Reiber, S. Venuraju, A. Yerramasu, S. Atwal, A. Lahiri, T. Kunimasa, M. Shiba, K. Ishii, J. Aikawa, E. S. J. Kroner, K. T. Ho, Q. W. Yong, K. C. Chua, C. Panknin, C. J. Roos, J. M. Van Werkhoven, A. J. Witkowska-Grzeslo, M. J. Boogers, D. V. Anand, D. Dey, D. Berman, F. Mut, R. Giubbini, L. Lusa, T. Massardo, A. Iskandrian, M. Dondi, A. Sato, Y. Kakefuda, E. Ojima, T. Adachi, A. Atsumi, T. Ishizu, Y. Seo, M. Hiroe, K. Aonuma, M. Kruk, R. Pracon, C. Kepka, J. Pregowski, A. Kowalewska, M. Pilka, M. Opolski, I. Michalowska, Z. Dzielinska, M. Demkow, V. Stoll, N. Sabharwal, A. Chakera, O. Ormerod, H. Fernandes, M. Bernardes, E. Martins, P. Oliveira, T. Vieira, G. Terroso, A. Oliveira, T. Faria, F. Ventura, J. Pereira, S. Fukuzawa, M. Inagaki, J. Sugioka, A. Ikeda, S. Okino, J. Maekawa, T. Uchiyama, N. Kamioka, S. Ichikawa, M. Afshar, R. Alvi, N. Aguilar, R. Ippili, H. Shaqra, J. Bella, N. Bhalodkar, A. Dos Santos, M. Daicz, L. O. Cendoya, H. G. Marrero, J. Casuscelli, M. Embon, G. Vera Janavel, E. Duronto, E. P. Gurfinkel, C. M. Cortes, Y. Takeishi, K. Nakajima, Y. Yamasaki, T. Nishimura, K. Hayes Brown, F. Collado, M. Alhaji, J. Green, S. Alexander, R. Vashistha, S. Jain, F. Aldaas, J. Shanes, R. Doukky, K. Ashikaga, Y. J. Akashi, M. Uemarsu, R. Kamijima, K. Yoneyama, K. Omiya, Y. Miyake, Y. Brodov, U. Raval, A. Berezin, V. Seden, E. Koretskaya, T. A. Panasenko, S. Matsuo, S. Kinuya, J. Chen, R. J. Van Bommel, B. Van Der Hiel, P. Dibbets-Schneider, E. V. Garcia, I. Rutten-Vermeltfoort, M. M. J. Gevers, B. Verhoeven, A. B. Dijk Van, E. Raaijmakers, P. G. H. M. Raijmakers, J. E. Engvall, M. Gjerde, J. De Geer, E. Olsson, P. Quick, A. Persson, M. Mazzanti, M. Marini, L. Pimpini, G. P. Perna, C. Marciano, P. Gargiulo, M. Galderisi, C. D'amore, G. Savarese, L. Casaretti, S. Paolillo, A. Cuocolo, P. Perrone Filardi, M. Al-Amoodi, E. C. Thompson, K. Kennedy, K. A. Bybee, A. I. Mcghie, J. H. O'keefe, T. M. Bateman, R. L. F. Van Der Palen, A. M. Mavinkurve-Groothuis, B. Bulten, L. Bellersen, H. W. M. Van Laarhoven, L. Kapusta, L. F. De Geus-Oei, P. P. Pollice, M. B. Bonifazi, F. P. Pollice, I. P. Clements, D. O. Hodge, C. G. Scott, M. De Ville De Goyet, B. Brichard, T. Pirotte, S. Moniotte, R. A. Tio, A. Elvan, R. A. I. O. Dierckx, R. H. J. A. Slart, T. Furuhashi, M. Moroi, H. Hase, N. Joki, H. Masai, R. Nakazato, H. Fukuda, K. Sugi, K. Kryczka, E. Kaczmarska, J. Petryka, L. Mazurkiewicz, W. Ruzyllo, P. Smanio, E. Vieira Segundo, M. Siqueira, J. Kelendjian, J. Ribeiro, J. Alaca, M. Oliveira, F. Alves, I. Peovska, J. Maksimovic, M. Vavlukis, N. Kostova, D. Pop Gorceva, V. Majstorov, M. Zdraveska, S. Hussain, M. Djearaman, E. Hoey, L. Morus, O. Erinfolami, A. Macnamara, M. P. Opolski, A. Witkowski, V. Berti, F. Ricci, R. Gallicchio, W. Acampa, G. Cerisano, C. Vigorito, R. Sciagra', A. Pupi, H. Sliem, F. M. Collado, S. Schmidt, A. Maheshwari, R. Kiriakos, V. Mwansa, S. Ljubojevic, S. Sedej, M. Holzer, G. Marsche, V. Marijanski, J. Kockskaemper, B. Pieske, A. Ricalde, G. Alexanderson, A. Mohani, P. Khanna, A. Sinusas, F. Lee, V. A. Pinas, B. L. F. Van Eck-Smit, H. J. Verberne, C. M. De Bruin, G. Guilhermina, L. Jimenez-Angeles, O. Ruiz De Jesus, O. Yanez-Suarez, E. Vallejo, E. Reyes, M. Chan, M. L. Hossen, S. R. Underwood, A. Karu, S. Bokhari, V. Pineda, L. M. Gracia-Sanchez, A. Garcia-Burillo, K. Zavadovskiy, Y. U. Lishmanov, W. Saushkin, I. Kovalev, A. Chernishov, A. Annoni, M. Tarkia, T. Saanijoki, V. Oikonen, T. Savunen, M. A. Green, M. Strandberg, A. Roivainen, M. C. Gaeta, C. Artigas, J. Deportos, L. Geraldo, A. Flotats, V. La Delfa, I. Carrio, W. J. Laarse, M. M. Izquierdo Gomez, J. Lacalzada Almeida, A. Barragan Acea, A. De La Rosa Hernandez, R. Juarez Prera, G. Blanco Palacios, J. A. Bonilla Arjona, J. J. Jimenez Rivera, J. L. Iribarren Sarrias, I. Laynez Cerdena, A. Dedic, A. Rossi, G. J. R. Ten Kate, A. Dharampal, A. Moelker, T. W. Galema, N. Mollet, P. J. De Feyter, K. Nieman, D. Trabattoni, A. Broersen, M. Frenay, M. M. Boogers, P. H. Kitslaar, J. Dijkstra, D. A. Annoni, M. Muratori, N. Johki, M. Tokue, A. S. Dharampal, A. C. Weustink, L. A. E. Neefjes, S. L. Papadopoulou, C. Chen, N. R. A. Mollet, E. H. Boersma, G. P. Krestin, J. A. Purvis, D. Sharma, S. M. Hughes, D. S. Berman, R. Taillefer, J. Udelson, M. Devine, J. Lazewatsky, G. Bhat, D. Washburn, D. Patel, T. Mazurek, S. Tandon, S. Bansal, S. Inzucchi, L. Staib, J. Davey, D. Chyun, L. Young, F. Wackers, M. T. Harbinson, G. Wells, J. Dougan, S. Borges-Neto, H. Phillips, A. Farzaneh-Far, Z. Starr, L. K. Shaw, M. Fiuzat, C. O'connor, M. Henzlova, W. L. Duvall, A. Levine, U. Baber, L. Croft, S. Sahni, S. Sethi, L. Hermann, A. Nureldin, A. Gomaa, M. A. T. Soliman, H. A. R. Hany, F. De Graaf, A. Pazhenkottil, H. M. J. Siebelink, J. H. Reiber, M. Ayub, T. Naveed, M. Azhar, A. Van Tosh, T. L. Faber, J. R. Votaw, N. Reichek, B. Pulipati, C. Palestro, K. J. Nichols, K. Okuda, Y. Kirihara, T. Ishikawa, J. Taki, M. Yoshita, M. Yamada, A. Salacata, S. Keavey, V. Chavarri, J. Mills, H. Nagaraj, P. Bhambhani, D. E. Kliner, P. Soman, J. Heo, A. E. Iskandrian, M. Jain, B. Lin, A. Walker, C. Nkonde, S. Bond, A. Baskin, J. Declerck, M. E. Soto, G. Mendoza, M. Aguilar, S. P. Williams, G. Colice, J. R. Mcardle, A. Lankford, D. K. Kajdasz, C. R. Reed, L. Angelini, F. Angelozzi, G. Ascoli, A. Jacobson, H. J. Lessig, M. C. Gerson, M. D. Cerqueira, J. Narula, M. Uematsu, K. Kida, K. Suzuki, P. E. Bravo, K. Fukushima, M. Chaudhry, J. Merrill, A. Alonso Tello, J. F. Rodriguez Palomares, G. Marti Aguasca, S. Aguade Bruix, V. Aliaga, P. Mahia, T. Gonzalez-Alujas, J. Candell, A. Evangelista, R. Mlynarski, A. Mlynarska, M. Sosnowski, B. Zerahn, P. Hasbak, C. E. Mortensen, H. F. Mathiesen, M. Andersson, D. Nielsen, L. Ferreira Santos, M. J. Ferreira, D. Ramos, D. Moreira, M. J. Cunha, A. Albuquerque, A. Moreira, J. Oliveira Santos, G. Costa, L. A. Providencia, Y. Arita, S. Kihara, N. Mitsusada, M. Miyawaki, H. Ueda, H. Hiraoka, Y. Matsuzawa, J. Askew, M. O'connor, L. Jordan, R. Ruter, R. Gibbons, T. Miller, L. Emmett, A. Ng, N. Sorensen, R. Mansberg, L. Kritharides, T. Gonzalez, H. Majmundar, N. P. Coats, S. Vernotico, J. H. Doan, T. M. Hernandez, M. Evini, A. D. Hepner, T. K. Ip, W. A. Chalela, A. M. Falcao, L. O. Azouri, J. A. F. Ramires, J. C. Meneghetti, F. Manganelli, M. Spadafora, P. Varrella, G. Peluso, R. Sauro, E. Di Lorenzo, F. Rotondi, S. Daniele, P. Miletto, A. J. M. Rijnders, B. W. Hendrickx, W. Van Der Bruggen, Y. G. C. J. America, P. J. Thorley, F. U. Chowdhury, C. J. Dickinson, S. I. Sazonova, I. Y. U. Proskokova, A. M. Gusakova, S. M. Minin, Y. U. B. Lishmanov, V. V. Saushkin, G. Rodriguez, F. Roffe, H. Ilarraza, D. Bialostozky, A. N. Kitsiou, P. Arsenos, I. Tsiantis, S. Charizopoulos, S. Karas, R. C. Vidal Perez, M. Garrido, V. Pubul, S. Argibay, C. Pena, M. Pombo, A. B. Ciobotaru, A. Sanchez-Salmon, A. Ruibal Morell, J. R. Gonzalez-Juanatey, E. Rodriguez-Gomez, B. Martinez, D. Pontillo, F. Benvissuto, F. Fiore Melacrinis, S. Maccafeo, E. V. Scabbia, R. Schiavo, Y. Golzar, C. Gidea, J. Golzar, D. Pop-Gorceva, M. Zdravkovska, S. Stojanovski, L. J. Georgievska-Ismail, T. Katsikis, A. Theodorakos, A. Kouzoumi, M. Koutelou, Y. Yoshimura, T. Toyama, H. Hoshizaki, S. Ohshima, M. Inoue, T. Suzuki, A. Uitterdijk, M. Dijkshoorn, M. Van Straten, W. J. Van Der Giessen, D. J. Duncker, D. Merkus, G. Platsch, J. Sunderland, C. Tonge, P. Arumugam, T. Dey, H. Wieczorek, R. Bippus, R. L. Romijn, B. E. Backus, T. Aach, M. Lomsky, L. Johansson, J. Marving, S. Svensson, J. L. Pou, F. P. Esteves, P. Raggi, R. Folks, Z. Keidar, J. W. Askew, L. Verdes, L. Campos, V. Gulyaev, A. Pankova, J. Santos, S. Carmona, I. Henriksson, A. Prata, M. Carrageta, A. I. Santos, K. Yoshinaga, M. Naya, C. Katoh, O. Manabe, S. Yamada, H. Iwano, S. Chiba, H. Tsutsui, N. Tamaki, I. Vassiliadis, E. Despotopoulos, O. Kaitozis, E. Hatzistamatiou, R. Thompson, J. Hatch, M. Zink, B. S. Gu, G. D. Bae, C. M. Dae, G. H. Min, E. J. Chun, S. I. Choi, M. Al-Mallah, K. Kassem, O. Khawaja, D. Goodman, D. Lipkin, L. Christiaens, B. Bonnet, J. Mergy, D. Coisne, J. Allal, N. Dias Ferreira, D. Leite, J. Rocha, M. Carvalho, D. Caeiro, N. Bettencourt, P. Braga, V. Gama Ribeiro, U. S. Kristoffersen, A. M. Lebech, H. Gutte, R. S. Ripa, N. Wiinberg, C. L. Petersen, G. Jensen, A. Kjaer, C. Bai, R. Conwell, R. D. Folks, L. Verdes-Moreiras, D. Manatunga, A. F. Jacobson, D. Belzer, Y. Hasid, M. Rehling, R. H. Poulsen, L. Falborg, J. T. Rasmussen, L. N. Waehrens, C. W. Heegaard, J. M. U. Silvola, S. Forsback, J. O. Laine, S. Heinonen, S. Ylaherttuala, A. Broisat, M. Ruiz, N. C. Goodman, J. Dimastromatteo, D. K. Glover, F. Hyafil, F. Blackwell, G. Pavon-Djavid, L. Sarda-Mantel, L. J. Feldman, A. Meddahi-Pelle, V. Tsatkin, Y.- H. Liu, R. De Kemp, P. J. Slomka, R. Klein, G. Germano, R. S. Beanlands, A. Rohani, V. Akbari, J. G. J. Groothuis, M. Fransen, A. M. Beek, S. L. Brinckman, M. R. Meijerink, M. B. M. Hofman, C. Van Kuijk, S. Kogure, E. Yamashita, J. Murakami, R. Kawaguchi, H. Adachi, S. Oshima, S. Minin, S. Popov, Y. U. Saushkina, G. Savenkova, D. Lebedev, E. Alexandridis, D. Rovithis, C. Parisis, I. Sazonova, V. Saushkin, V. Chernov, L. Zaabar, H. Bahri, S. Hadj Ali, A. Sellem, I. Slim, N. El Kadri, H. Slimen, H. Hammami, S. Lucic, A. Peter, S. Tadic, K. Nikoletic, R. Jung, M. Lucic, K. Tagil, D. Jakobsson, S.- E. Svensson, P. Wollmer, L. Leccisotti, L. Indovina, L. Paraggio, M. L. Calcagni, A. Giordano, M. Kapitan, A. Paolino, M. Nunez, J. Sweeny, N. Kulkarni, K. Guma, Y. Akashi, M. Takano, M. Takai, S. Koh, F. Miyake, N. Torun, G. Durmus Altun, A. Altun, E. Kaya, H. Saglam, D. T. Matsuoka, A. Sanchez, C. Bartolozzi, D. Padua, G. Ponta, A. Ponte, A. Carneiro, A. Thom, R. Ashrafi, P. Garg, G. Davis, A. Falcao, M. Costa, F. Bussolini, J. A. C. Meneghetti, M. Tobisaka, E. Correia, J. W. Jansen, P. A. Van Der Vleuten, T. P. Willems, F. Zijlstra, M. Sato, K. Taniguchi, M. Kurabayashi, D. Pop Gjorcheva, M. Zdraveska-Kochovska, K. Moriwaki, A. Kawamura, K. Watanabe, T. Omura, S. Sakabe, T. Seko, A. Kasai, M. Ito, M. Obana, T. Akasaka, C. Hruska, D. Truong, C. Pletta, D. Collins, C. Tortorelli, D. Rhodes, M. El-Prince, A. Martinez-Moeller, M. Marinelli, S. Weismueller, C. Hillerer, B. Jensen, S. G. Nekolla, H. Wakabayashi, K. Tsukamoto, S. M. E. A. Baker, K. M. H. S. Sirajul Haque, A. Siddique, S. Krishna Banarjee, A. Ahsan, F. Rahman, M. Mukhlesur Rahman, T. Parveen, M. Lutfinnessa, F. Nasreen, H. Sano, S. Naito, M. L. De Rimini, G. Borrelli, F. Baldascino, P. Calabro, C. Maiello, A. Russo, C. Amarelli, P. Muto, I. Danad, P. G. Raijmakers, Y. E. Appelman, O. S. Hoekstra, J. T. Marcus, A. Boonstra, D. V. Ryzhkova, T. V. Kuzmina, O. S. Borodina, M. A. Trukshina, I. S. Kostina, H. Hommel, G. Feuchtner, O. Pachinger, G. Friedrich, A. M. Stel, J. W. Deckers, V. Gama, A. Ciarka, L. A. Neefjes, N. R. Mollet, E. J. Sijbrands, J. Wilczek, C. Llibre Pallares, O. Abdul-Jawad Altisent, H. Cuellar Calabria, P. Mahia Casado, M. T. Gonzalez-Alujas, A. Evangelista Masip, D. Garcia-Dorado Garcia, Y. Tekabe, X. Shen, Q. Li, J. Luma, D. Weisenberger, A. M. Schmidt, R. Haubner, L. Johnson, L. Sleiman, S. Thorn, M. Hasu, M. Thabet, J. N. Dasilva, S. C. Whitman, D. Genovesi, A. Giorgetti, A. Gimelli, G. Cannizzaro, F. Bertagna, G. Fagioli, M. Rossi, R. Bonini, P. Marzullo, C. A. Paterson, S. A. Smith, A. D. Small, N. E. R. Goodfield, W. Martin, S. Nekolla, H. Sherif, S. Reder, M. Yu, A. Kusch, D. Li, J. Zou, M. S. Lloyd, K. Cao, D. W. Motherwell, A. Rice, G. M. Mccurrach, S. M. Cobbe, M. C. Petrie, I. Al Younis, E. Van Der Wall, T. Mirza, M. Raza, H. Hashemizadeh, L. Santos, B. A. Krishna, F. Perna, M. Lago, M. Leo, G. Pelargonio, G. Bencardino, M. L. Narducci, M. Casella, F. Bellocci, S. Kirac, O. Yaylali, M. Serteser, T. Yaylali, A. Okizaki, Y. Urano, M. Nakayama, S. Ishitoya, J. Sato, Y. Ishikawa, M. Sakaguchi, N. Nakagami, T. Aburano, S. V. Solav, R. Bhandari, S. Burrell, S. Dorbala, I. Bruno, C. Caldarella, A. Collarino, M. V. Mattoli, A. Stefanelli, A. Cannarile, F. Maggi, V. Soukhov, S. Bondarev, A. Yalfimov, M. Khan, P. P. Priyadharshan, G. Chandok, T. Aziz, M. Avison, R. A. Smith, D. S. Bulugahapitya, T. Vakhtangadze, F. Todua, M. Baramia, G. Antelava, N.- C. Roche, P. Paule, S. Kerebel, J.- M. Gil, L. Fourcade, A. Tzonevska, K. Tzvetkov, M. Atanasova, V. Parvanova, A. Chakarova, E. Piperkova, B. Kocabas, H. Muderrisoglu, C. P. Allaart, E. Entok, S. Simsek, B. Akcay, I. Ak, E. Vardareli, M. Stachura, P. J. Kwasiborski, G. J. Horszczaruk, E. Komar, A. Cwetsch, B. Zraik, R. Morales Demori, A. D. J. Almeida, M. E. Siqueira, E. Vieira, I. Balogh, G. Kerecsen, E. Marosi, Z. S. Szelid, A. Sattar, T. Swadia, J. Chattahi, W. Qureshi, F. Khalid, A. Gonzalez, S. Hechavarria, K. Takamura, S. Fujimoto, R. Nakanishi, S. Yamashina, A. Namiki, J. Yamazaki, K. Koshino, Y. Hashikawa, N. Teramoto, M. Hikake, S. Ishikane, T. Ikeda, H. Iida, Y. Takahashi, N. Oriuchi, H. Higashino, K. Endo, T. Mochizuki, K. Murase, A. Baali, R. Moreno, M. Chau, H. Rousseau, F. Nicoud, P. Dolliner, L. Brammen, G. Steurer, T. Traub-Weidinger, P. Ubl, P. Schaffarich, G. Dobrozemsky, A. Staudenherz, M. Ozgen Kiratli, B. Temelli, N. B. Kanat, T. Aksoy, G. A. Slavich, G. Piccoli, M. Puppato, S. Grillone, D. Gasparini, S. Perruchoud, C. Poitry-Yamate, M. Lepore, R. Gruetter, T. Pedrazzini, D. Anselm, A. Anselm, H. Atkins, J. Renaud, R. Dekemp, I. Burwash, A. Guo, R. Beanlands, C. Glover, I. Vilardi, B. Zangheri, L. Calabrese, P. Romano, A. Bruno, O. C. Fernandez Cimadevilla, V. A. Uusitalo, M. Luotolahti, M. Wendelin-Saarenhovi, J. Sundell, O. Raitakari, S. Huidu, R. Gadiraju, M. Ghesani, Q. Uddin, B. Wosnitzer, N. Takahashi, E. Alhaj, A. Legasto, B. Abiri, K. Elsaban, T. El Khouly, T. El Kammash, A. Al Ghamdi, B. Kyung Deok, K. Bon Seung, Y. Sang Geun, D. Chang Min, and M. Gwan Hong
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2011
- Full Text
- View/download PDF
44. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia
- Author
-
Massimo Raffaele Mannarino, Matteo Pirro, Donatella Siepi, G. Savarese, Elmo Mannarino, Rita Paltriccia, Gaetano Vaudo, and Giuseppe Schillaci
- Subjects
Adult ,Male ,medicine.medical_specialty ,Statin ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Hypercholesterolemia ,Medicine (miscellaneous) ,chemistry.chemical_compound ,medicine.artery ,Internal medicine ,Humans ,Medicine ,Rosuvastatin ,Prospective Studies ,Rosuvastatin Calcium ,Diet, Fat-Restricted ,Pulse wave velocity ,Aorta ,Aged ,Sulfonamides ,Nutrition and Dietetics ,business.industry ,Cholesterol ,Nitrotyrosine ,nutritional and metabolic diseases ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Fluorobenzenes ,Pyrimidines ,Treatment Outcome ,chemistry ,Pulsatile Flow ,Arterial stiffness ,Cardiology ,Tyrosine ,Female ,Aortic stiffness ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,Compliance ,medicine.drug - Abstract
Background and aims Early atherosclerosis is characterized by reduced large artery distensibility, paralleled by an increased peroxynitrite formation and nitration of tyrosine in proteins. The aim of the present study was to investigate the short-term effect of cholesterol lowering with rosuvastatin on 3-nitrotyrosine (3-NT), a marker of peroxynitrite-mediated oxidative stress, and on arterial stiffness. Methods and results 71 outpatients with primary hypercholesterolemia were recruited for this randomized open-label intervention study; 35 patients were assigned to 4-week rosuvastatin therapy (10 mg daily) with a low-fat diet, and 36 patients to a low-fat diet only. Within the cohort of 71 hypercholesterolemic patients, there was a significant correlation between cholesterol levels, 3-NT and aortic pulse wave velocity (aPWV), that is a reliable measure of aortic stiffness. Among those patients who received rosuvastatin, significant reductions in plasma cholesterol, 3-NT and aPWV were observed. Reductions in both aPWV and 3-NT levels correlated significantly with the decrease in plasma cholesterol. Reduction of plasma cholesterol was the only independent predictor for reduced arterial stiffness following rosuvastatin therapy. Conclusion Cholesterol reduction achieved following short-term rosuvastatin therapy is associated with a decrease in peroxynitrite-mediated oxidative stress and an improvement in large artery distensibility; reduction in arterial stiffness is directly attributable to rosuvastatin-induced cholesterol lowering and not to reduction of plasma 3-NT levels.
- Published
- 2007
- Full Text
- View/download PDF
45. Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia
- Author
-
Giuseppe Schillaci, G. Savarese, Francesco Bagaglia, Massimo Raffaele Mannarino, Fabio Gemelli, Matteo Pirro, Elmo Mannarino, and Donatella Siepi
- Subjects
medicine.medical_specialty ,Epidemiology ,Saturated fat ,Hypercholesterolemia ,Blood lipids ,Blood Pressure ,Inflammation ,Systemic inflammation ,Body Mass Index ,Cholesterol, Dietary ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Diet, Fat-Restricted ,Cholesterol ,business.industry ,Arteries ,Middle Aged ,medicine.disease ,C-Reactive Protein ,Endocrinology ,chemistry ,Heart failure ,Multivariate Analysis ,Cardiology ,Arterial stiffness ,Vascular Resistance ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,business ,Cardiology and Cardiovascular Medicine ,Body mass index - Abstract
Increased arterial stiffness has been found in patients with chronic high-grade inflammatory diseases. Whether mitigation of low-grade systemic inflammation, through a low-cholesterol/low-saturated fat diet, may have a role in improving arterial stiffness is still untested.We investigated whether variations in blood lipids and plasma C-reactive protein induced by low-cholesterol/low-saturated fat diet are associated with variations in large-artery stiffness in hypercholesterolaemia.Thirty-five patients with primary hypercholesterolaemia and 15 normal control subjects were recruited for the study. Hypercholesterolaemic patients followed an 8-week low-cholesterol/low-saturated fat diet (30% total fat, 5% saturated fat, cholesterol200 mg/daily). Anthropometric characteristics, blood lipids, plasma C-reactive protein and arterial stiffness were measured at baseline and after the diet.Arterial stiffness and C-reactive protein levels were higher in hypercholesterolaemic patients than in controls. Significant reductions in body weight (2 kg, 3%), plasma total cholesterol (13.4 mg/dl, 5.3%), low-density lipoprotein cholesterol (11.2 mg/dl, 6.4%), C-reactive protein (0.7 mg/l, 39%) and arterial stiffness (from 8.9+/-2.0 to 8.1+/-1.9 m/s, 11%) were achieved among hypercholesterolaemic patients after the 8-week diet (P0.05 for all). Bivariate correlations and multivariate analysis showed reduction in arterial stiffness after short-term diet to be associated with reduction of plasma C-reactive protein levels (r=0.59, beta=0.38, P0.05 for both).Short-term low-cholesterol/low-saturated fat diet in hypercholesterolaemia may be effective in improving large artery stiffness, likely through the mitigation of low-grade systemic inflammation.
- Published
- 2004
- Full Text
- View/download PDF
46. Left ventricular hypertophy regression and cardiovascular outcomes. A meta-analysis
- Author
-
P. Costanzo, S. Paolillo, E. Vassallo, P. Cesarano, F. Marsico, G. Savarese, A. Marzano, M. Chiariello, PERRONE FILARDI, PASQUALE, P., Costanzo, PERRONE FILARDI, Pasquale, S., Paolillo, E., Vassallo, P., Cesarano, F., Marsico, G., Savarese, A., Marzano, and M., Chiariello
- Published
- 2010
47. 186All-cause mortality in cardiac resynchronization therapy is predicted by the degree of LV reverse remodeling at mid-term follow-up
- Author
-
Albino Reggiani, Maurizio Malacrida, Luca Checchi, Attilio Pierantozzi, Antonio Rapacciuolo, M. Pasqualini, S. Quintarelli, Matteo Santamaria, Ludovico Vasquez, G. Savarese, Giuseppe Stabile, G. Saggese, Giuseppe Arena, Giampiero Maglia, and Francesco Solimene
- Subjects
medicine.medical_specialty ,Mid term follow up ,business.industry ,Physiology (medical) ,Internal medicine ,medicine.medical_treatment ,medicine ,Cardiology ,Cardiac resynchronization therapy ,Cardiology and Cardiovascular Medicine ,Reverse remodeling ,business ,Degree (temperature) - Published
- 2017
- Full Text
- View/download PDF
48. La disfunzione endoteliale è associata alla malattia coronarica e correla con il controllo glicemico in pazienti con diabete mellito di tipo 2
- Author
-
MARCIANO, CATERINA, PERRONE FILARDI, PASQUALE, GARGIULO, PAOLA, DELLEGROTTAGLIE, SANTO, COSTANZO, PIERLUIGI, CHIARIELLO, MASSIMO, G. Savarese, C. D'Amore, M. Santomauro, Marciano, Caterina, PERRONE FILARDI, Pasquale, Gargiulo, Paola, G., Savarese, C., D'Amore, Dellegrottaglie, Santo, Costanzo, Pierluigi, M., Santomauro, and Chiariello, Massimo
- Subjects
"diabete mellito" ,"malattia coronarica" ,"disfunzione endoteliale" - Published
- 2009
49. Una insospettabile signora chiamata disfunzione diastolica
- Author
-
PERRONE FILARDI, PASQUALE, PAOLILLO, STEFANIA, MARSICO, FABIO, VASSALLO, ENRICO, SCALA, ORIANA, RUGGIERO, DONATELLA, CHIARIELLO, MASSIMO, G. Savarese, C. D’Amore, A. Parente, T. Losco, PERRONE FILARDI, Pasquale, Paolillo, Stefania, G., Savarese, C., D’Amore, A., Parente, Marsico, Fabio, Vassallo, Enrico, Scala, Oriana, Ruggiero, Donatella, T., Losco, and Chiariello, Massimo
- Published
- 2009
50. Relazione tra emoglobina glicosilata e funzione endoteliale valutata con tonometria digitale
- Author
-
G. Savarese, C. D'Amore, M. Santomauro, PERRONE FILARDI, PASQUALE, MARCIANO, CATERINA, GARGIULO, PAOLA, COSTANZO, PIERLUIGI, CHIARIELLO, MASSIMO, G., Savarese, PERRONE FILARDI, Pasquale, Marciano, Caterina, Gargiulo, Paola, C., D'Amore, Costanzo, Pierluigi, M., Santomauro, and Chiariello, Massimo
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.